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ABSTRACT
In the current dissertation, closely related studies to quantify the mechanism
underlying enzyme evolution have been discussed. The HIV-1 protease and !-lactamase
enzymes were used as model systems for these studies. These are well known enzymes
that are associated with drug resistance and are associated with the pathogenic diseases,
and therefore, developing molecular level understanding of drug resistance through these
enzymes has fundamental as well as practical importance.
In chapter 2, the relationship between errors in modeled protein structures and
associated binding affinity predictions to small molecules is established. The results of
this study are applicable in addressing a wide range of biological questions including
enzyme evolutionary mechanisms. The next three chapters discuss different aspects of
HIV-1 protease evolution. In chapter 3, the role of substrate binding in manipulating the
catalytic activity of HIV-1 protease during evolution has been examined. The results
suggest that HIV-1 protease can optimize its catalytic activity by manipulating its
substrate binding affinity. This part of study also emphasizes the importance of
considering the in-vivo environment while studying physical-chemical aspects of
enzymatic evolution. In chapter 4, the role of dynamics as a constraint on the evolution of
HIV-1 protease has been examined. Low frequency motions (dynamics) of an enzyme
have been suggested to be critical for its function. It has been further suggested that any
mutation that disrupts these low frequency motions may have an adverse affect on the
catalytic function of the enzyme. In this part of study, the role of dynamics as a constraint
on the evolution of HIV-1 protease has been examined by comparing experimental
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activity data for over 90 mutants of HIV-1 protease to correlated motion data obtained
from molecular dynamics simulations of a Michaelis complex. The results of this study
suggest that dynamics do not impose a significant constraint on the evolution of HIV-1
protease. In chapter 5, the role of fold stability as a constraint on the evolution of HIV-1
protease is examined. A significant tradeoff between evolvability and fold stability for
HIV-1 protease was observed in our study. The results of this study suggest that fold
stability imposes a significant constraint on the evolution of HIV-1 protease, and in future
attempts to predict evolutionary outcomes (drug resistant mutations), fold stability should
also be taken into consideration. In chapter 6, the evolution of cefotaximase activity
within !-lactamase is described. !-lactamase is a bacterial enzyme that catalytically
hydrolyzes the !-lactam antibiotic, and therefore inactivates these drugs. Five point
mutations are, however, required in the gene of this enzyme in order to develop
cefotaximase activity. In this part of our study, we have studied the effect of four drug
resistant amino acid mutations [A42G, E104K, G238S, and M182T] on the structural
properties and cefotaximase activity of !-lactamase. Along with the successful
identification of evolutionary beneficial mutations, our analyses suggest structural
rearrangement within active site as a possible mechanism for increasing the activity
against cefotaxime.
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CHAPTER ONE

INTRODUCTION

Enzymes are characterized as specific (recognition of substrates), accurate
(catalysis of chemical reactions), and proficient (acceleration of chemical reactions) in
their ability to catalyze the biochemical reactions. Enzymes accelerate the rate of
biochemical reactions to a timescale necessary for living organisms under physiological
conditions. Enzymes further act as the regulatory units for biochemical processes by
controlling the relative abundance of the chemical species in the cell. And therefore, the
enzymatic reactions have very fundamental roles to play in controlling and performing
most biological processes[1, 2].
The specificity, accuracy, and proficiency in the function of an enzyme come at
the cost of its versatility. During the evolution of an organism, the phenotypic properties
of its functional components (which include enzymes) change to acquire the ability to
optimally perform the respective functions relevant to its new environment. The
variations in genetic sequences encoding enzymes, which result in new functional
capabilities, is termed as “enzymatic evolution”[3]. Enzymatic evolution under strong
selection plays a critical role in the development of drug resistance in viruses and
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bacteria[4-6]. Considering these facts, developing a molecular level understanding of the
principles governing enzymatic evolution has both fundamental and practical importance.
Until very recently, the understanding of evolution was limited to the analyses of
evolutionary outcomes. However, the synthesis of evolutionary biology and experimental
molecular biology (functional synthesis) have brought a new and exciting era in the study
of evolution[7]. The empirical fitness landscapes of enzymatic evolution, which were
constructed using this approach, have provided new insights into enzymatic evolution by
exploring evolutionary intermediates and pathways[7, 8]. A detailed discussion about the
functional synthesis approach and its applications can be found in a review by Dean and
Thornton[7]. Some of the very fundamental questions regarding fitness landscapes of
enzymatic evolution and accessible evolutionary pathways from suboptimal allele to
optimal allele for enzymes have been successfully addressed using the functional
synthesis approach[7, 8]. Growing experimental information about evolutionary
intermediates and pathways of enzymes has provided a firm basis for molecular level
analysis of enzymatic evolution.
The theoretical and computational approaches to study the biological processes
not only provide a molecular level insight into the process of interest, but also shed light
on the microscopic origin of its driving force. A very detailed discussion about several
aspects of computational biology can be found in a special issue edited by Christopher
Surridge in Nature Insight Nov 2002[9]. Recent advancements in the computational
modeling, simulation and free energy estimation techniques, in conjunction with
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transition state theory, have provided new insights into catalytic process of enzymes. The
proposal for enzyme catalysis has evolved from “...the entire and sole source of catalytic
power [of enzymes] is the stabilization of the transtion state ..”[10] to “The entire and
sole source of the catalytic power of enzymes is due to the lowering of the free energy of
activation and any increase in the generalized transmission coefficient, as compared to
that of uncatalyzed reaction.”[11]. The computational techniques have also been shown
to be successful in predicting the effect of amino acid mutations on catalytic efficiency of
enzymes[12, 13].
The development of a physical-chemical model which can accurately explain
enzymatic evolution and can help in predicting the evolutionary outcome of an enzyme
under strong selection has a great deal of implications. With the aim to help developing
such model, the research presented in current dissertation focuses on the quantification of
the mechanism underlying enzymatic evolution, using computational techniques.
Starting with the chapter 2, we have first assessed the effect of errors in modeled
protein structures on binding affinity predictions to small molecules. A huge gap exists
between the number of known sequences and number of known three dimensional
structures of proteins. This structure-sequence gap brings computational structure
prediction algorithms into perspective, which provide a relatively quick and economical
solution to this problem[14]. However, the computational modeling techniques use
various approximations, which almost always result in some error in the modeled
structure[15]. As modeled structures are frequently used in the calculation of binding
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affinities to small molecules, information relating the accuracy of these calculations to
the structural accuracy of the model would be a valuable component in these studies.
With the help of molecular dynamics simulations and computational free energy
estimation techniques, the relationship between protein structural error and resulting error
in binding affinity of small molecule has been established. The results of this study have
applicability in addressing a broad range of biological questions which involve estimation
of small molecule binding affinity with modeled structure.
In next three chapters, different aspects of the evolution of HIV-1 protease have
been studied. The HIV-1 protease catalyzes the hydrolysis of Gag and Gag-Pol
polyproteins of new virus at twelve different sites, and therefore has a key role to play in
viral maturation process[16]. The replication process of HIV-1 virus, however, is less
efficient and erroneous, which results in the rapid accumulation and selection of different
mutational variants of HIV-1 protease[5]. This process of accumulating mutants can be
seen as an evolutionary event. In the chapter 3, we have studied the evolution of catalytic
function in HIV-1 protease by examining the role of substrate and transition state binding
in describing the activities of different mutants of HIV-1 protease, within the context of
its biological environment. In the first step of our study, we have developed a numerical
model describing the activity of HIV-1 protease in the in-vivo condition, which suggested
that substrate binding could play a determining role in describing the catalytic activities
of mutant enzymes.

We have further emphasized the role of substrate binding by

predicting the relative activities of a statistically significant number of mutants based on
estimated change in substrate binding, along with change in transition state binding upon

4


these mutations. Further, in the study of 40 different amino acid mutations, no correlation
was observed between change in substrate and transition state binding. This suggests that
substrate specificity and catalytic activity in HIV-1 protease can be optimized
independently during the evolution.

This part of our study also emphasizes the

importance of considering the in-vivo environment while studying enzymatic evolution.
In the next part of our study, we have examined the role of dynamics as a
constraint on the evolution of HIV-1 protease. In a number of experimental and
theoretical studies, it has been suggested that the collective motions (dynamics) of
different segments of enzyme play a critical role in accelerating the reaction, and
disrupting these collective motions may adversely affect the rate of the reaction[17-19].
The correlated motions of the residues has been extensively used as the parameter for
characterizing the protein dynamics and it has been suggested that mutations in
negatively correlated regions can disrupt the catalytic activity of enzyme[20], and
therefore can impose a constraint on the evolution of an enzyme. In chapter 4, we have
examined the role of dynamics as a constraint on the evolution of HIV-1 protease by
comparing experimental data for over 90 mutants of HIV-1 protease[21], to correlated
motion data obtained from molecular dynamics simulations of the Michaelis complex.
The results from numerous analyses do not show any significant relationship between
correlated motion and enzyme activity for HIV-1 protease. And therefore, our study
suggests that dynamics does not impose any significant constraint on the evolution of
HIV-1 protease.
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In chapter 5, we have examined the role of fold stability on the evolvability
(ability of enzyme to acquire mutations) of HIV-1 protease. A change in fold stability of
an enzyme upon mutations can have a deleterious effect on its functional properties, and
therefore can impose significant constraints on its evolution[22]. Considering the fact that
HIV-1 protease is stable by only ~1.05 kcal/mol[23], the change in fold stability could
play a critical role in describing evolutionary pathways and outcomes of this enzyme. In
this part of our study, we have first examined the relationship between mutational effect
on catalytic efficiency and its effect on fold stability of HIV-1 protease. We observed a
significant correlation between loss in activity and decrease in fold stability. Further, we
have compared the mutational patterns in Stanford HIV-1 sequence database[24] to the
change in fold stability caused by relevant mutations, and observed a significant tradeoff
between evolvability and fold stability for HIV-1 protease. Our study suggests that fold
stability imposes a significant constraint on the evolution of HIV-1 protease, and in future
attempts to predict drug resistant mutations, fold stability should also be taken into
consideration.
In chapter 6, we shift our focus from HIV-1 protease to -lactamase. -lactamase
is a bacterial enzyme that causes resistance against -lactam antibiotic by catalytically
hydrolyzing these drugs[6, 25, 26]. Five point mutations are, however, required in the
gene of this enzyme in order to be able to efficiently hydrolyze cefotaxime (a third
generation cephalosporin-based antibiotic)[27, 28]. In an experimental study, it has been
shown that only selected mutational trajectories to these five point mutations are
assessable during the enzymatic evolution for resistance against cefotaxime[29].
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Therefore, developing a molecular level understanding of the acquisition process of drug
resistant mutations in -lactamase is not only critical in designing newer generation
antibiotic drugs, but also provides insight into evolutionary mechanism of enzymes. In
this part of our study, we have examined the effect of four drug resistant mutations
[A42G, E104K, G238S, and M182T] on the structural properties and cefotaximase
activity of -lactamase. We have been able to successfully identify the evolutionary
beneficial mutations (G238S and E104K) at the first step of evolution. In addition to this,
we have identified the structural rearrangement within active site as the plausible
mechanism for increasing the activity against cefotaxime.

This study has not only

provided a molecular level insight into the effect of four drug resistant mutations on the
structure and function of -lactamase, but also paved the way for future molecular level
analysis of a complete mutational trajectory for this class of enzyme.
In summary, the research presented in current dissertation provides molecular
level insight into the evolutionary mechanisms of HIV-1 protease and -lactamase.
Considering the pathological importance of these two enzymes, our research not only
brings new insight into evolution of enzymes in general, but also has implications in
developing strategies against the evolution of drug resistance associated with these
enzymes. More discussions about the research have been provided in the next chapters.
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CHAPTER TWO

THERMODYNAMIC RESOLUTION: HOW DO ERRORS IN MODELED
PROTEIN STRUCTURES AFFECT BINDING AFFINITY PREDICTIONS?
This work has been published as:
Singh, M.K and Dominy, B.N, Thermodynamic Resolution: How do Errors in Modeled
Protein Structures Affect Binding Affinity Predictions? Proteins, 2010, 78(7):1613-7
ABSTRACT

The present study addresses the effect of structural distortion, caused by protein
modeling errors, on calculated binding affinities toward small molecules. The binding
affinities to a total of 300 distorted structures based on five different protein-ligand
complexes were evaluated to establish a broadly applicable relationship between errors in
protein structure and errors in calculated binding affinities. Relatively accurate protein
models (less than 2 Å RMSD within the binding site) demonstrate a 14.78 (±7.5)%
deviation in binding affinity from that calculated by using the corresponding crystal
structure. For structures of 2-3 Å, 3-4 Å, and >4 Å RMSD within the binding site, the
error in calculated binding affinity increases to 20.8 (±5.98), 22.79 (±11.3), and 29.43
(±11.47)%, respectively. The results described here may be used in combination with
other tools to evaluate the utility of modeled protein structures for drug development or
other ligand-binding studies.
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INTRODUCTION
The determination of a three-dimensional structure from a novel protein sequence
is often a necessary step in quantifying molecular recognition and therefore key to
understanding its biological function. Computational methods that predict threedimensional protein structures have been enjoying a growing interest among researchers
recently, due to the rapidly growing body of sequence data and the time requirements of
current experimental structure determination methods. Homology modeling approaches
are widely used to generate high-resolution protein structural models[15, 30]. However,
de novo techniques and other classes of protein structure prediction algorithms continue
to show remarkable accomplishments and continuous progress[31].
Due to the various approximations used in computational structure prediction
methods, some error in modeled structures is always expected. Structural accuracy
assessment, therefore, has been considered an important step in protein modeling.
Significant efforts have been made to develop algorithms capable of efficiently assessing
the overall accuracy of modeled structures, and even the accuracy within particular
regions of interest such as binding sites[32, 33]. These algorithms are predictive and
provide an estimate of structural error without direct knowledge of the experimentally
determined structure.
Modeled protein structures are used in further analyses to address biophysical
questions. The degree of error that may be tolerated in the protein structure will be
dependent on the analyses for which these modeled structures are used as input. In
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addition to straightforward structural analyses, protein models are often used as the basis
for thermodynamic property calculations. The development of algorithms for predicting
the structural accuracy of protein models suggests the possibility of further assessing the
utility of these models for predicting thermodynamic quantities. As modeled protein
structures are often used in the calculation of binding affinities to small molecules,
information relating the accuracy of these calculations to the structural accuracy of the
model would be a valuable component in these investigations. Addressing this problem
for the end users of protein structural modeling, the present study has been designed to
systematically quantify the effect of structural distortion of protein models on the
calculated binding affinity toward small molecules.
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METHODS
A summary of the approach taken in this study is as follows. First, a group of five
structurally distinct protein–ligand complexes were chosen from the protein
databank[34]. The protein structures were then intentionally distorted to represent
modeled structures with some intrinsic error. The degree of distortion in the structures
was then quantified in terms of the root mean squared deviation (RMSD) of the binding
site residues. The binding free energy calculations were then performed on each of the
distorted complexes and compared to the binding free energy calculated from
corresponding crystal complexes. From these results, the error in calculated binding
affinities is related to the error in the structure.
1. Generating non-native structures
The PDB IDs of five protein–ligand complexes chosen for the present study are
1D7J, 5CYH, 2IFB, 1LKK, and 1FKF[34]. These complexes represent a variety of
protein classes including reductases, isomerases, fatty-acid binding proteins, and the
kinase SH2 domain. By investigating these complexes with distinct folds and ligand
structures (figure 2.1), the results of this study should be more generally applicable and
independent of the structural details of any particular protein.
In the process of generating the non-native (perturbed) structures, the crystal
structures of the protein components of all the five protein–ligand complexes were used.
The protein structures were initially minimized for 50 steps using a steepest descent (SD)
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algorithm to remove clashes. The systems were then gradually heated from 100 to 300 K
over 300 ps with an RMSD restraint on the binding site atoms, in order to perturb the
structure to a target RMSD value. The target RMSD values ranged from 1 to 6 Å. The
RMSD restraint was removed after heating, and the simulations were run for a further 2
ns to allow for equilibration. The implicit solvent GBSW[35] module in CHARMM[36]
was used to represent the implicit solvent environment while performing all energy
minimizations and molecular dynamics simulations. In addition, a cutoff of 16 Å was
used. The final structures of these simulations represent protein models with some
structural error and were used for calculation of RMSD values (relative to the crystal
structures), which are plotted on the x-axis of figures 2.2-2.8.
Although calculated binding affinities are sensitive to specific structural details,
the RMSD measure used to evaluate structural distortion is less sensitive. In order to
compensate for the coarse nature of the RMSD measure, multiple structures
corresponding to each target RMSD value were generated. The above procedure was
repeated using different combinations of the force constant, target RMSD value in the
RMSD restraint, and seed values for initial velocity assignments to generate a total of 319
perturbed structures. The large number of perturbed structures generated is used to
provide a statistically robust measure of the relationship between structural error and the
error in calculated binding affinities.
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Figure 2.1: The structures of the ligands used in the present study. (a) 4-hydroxy-2-butanone
(1D7J.pdb); (b) palmitic acid (2IFB.pdb); (c) GLY-PRO [5CYH.pdb]; (d) ACE-PTR-GLU-GLUILE (1LKK.pdb); and (e) 8-deethyl-8-(but-3-enyl)-ascomycin (1FKF.pdb).
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2. Modeling non-native protein–ligand complexes
The corresponding ligands were optimally replaced into the binding pocket of
each perturbed structure by superimposing the binding site atoms on the native protein–
ligand complex structure. Superimposition was performed by rotating and translating the
entire perturbed structure in order to minimize the binding site atomic RMSD toward the
native complex. The systems were then minimized for 500 steps using an SD algorithm
with a harmonic restraint applied to the protein component using a force constant of 10
kcal/mol/Å2.
3. Evaluating structural error
A quantitative measure of structural error is necessary to establish a relationship
between structural error and the error in a binding affinity calculation. In the present
study, structural distortion is quantified in terms of the RMSD with respect to the binding
site residues, defined as the amino acids for which at least one atom is within 4.5 Å of the
ligand in the reference structure. The binding site residue RMSD measure provides
information about atoms forming direct atomic interactions with the ligand and therefore
most relevant to binding. RMSD values for the binding site residues were assessed by
comparing the perturbed complex structures with the corresponding crystal complex.
These values were used for determining the effect of structural error on calculated
binding affinities.
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4. Calculating binding affinity using an MM-GBSA approach
Binding affinities calculated using a single trajectory MM-GBSA technique were
then determined for all 319 perturbed complexes and compared to the binding energy
calculated using the corresponding crystal structure. While the accuracy of such endpoint
methods have been questioned in the determination of absolute binding affinities, these
methods have been used successfully in evaluating relative binding affinities[37, 38]. In
addition, the focus of the current study is to evaluate the impact of structural error on
thermodynamic property calculations, and not to assess the accuracy of the
thermodynamic calculations themselves. Further, the inherent speed of the MM-GBSA
approach was necessary to arrive at a statistically meaningful result based on over 300
perturbed complex structures.
The binding affinities for the perturbed and crystal complexes were determined
using the following protocol. The complexes described above were gradually heated from
200 to 300 K over 200 ps with a weak harmonic restraint of 2 kcal/mol/Å2 applied to all
atoms of the protein component. The harmonic restraint was gradually removed over 200
ps of simulation followed by 3.6 ns of equilibration and 2 ns of production. 2000
snapshots extracted every 1 ps from each production run were used to estimate the
binding free energy using the MM-GBSA technique[39].
A detailed description of the MM-GBSA protocol can be found elsewhere[39-41].
In this study, gas phase energies of the each component (complex, protein, and ligand)
were calculated in CHARMM, using a nonbonded cutoff of 16 Å. The polar solvation
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energies were calculated using the GBSW module of CHARMM. The nonpolar solvation
energies were calculated separately using a solvent accessible surface area model with a
microscopic surface tension proportionality constant of 0.00542 kcal/mol/Å2 and a
correction factor of 0.92 kcal/mol, as described previously[42]. Entropy estimates were
calculated with the snapshots extracted every 40 ps from the production run. Vibrational
entropy terms were calculated by a normal mode approximation using the VIBRAN
module in CHARMM with a distance dependent dielectric using a coefficient of 4 and
nonbonded cutoff of 12 Å. Translational and rotational entropy components were also
estimated within the VIBRAN module of CHARMM.
For the analysis, the free energies were grouped into blocks corresponding to
structures of <2 Å, <3 Å, <4 Å, and >4 Å RMSD based on all atoms of the residues in the
binding site. The percent error in binding affinity was evaluated with respect to that of
calculated with crystal structure and averaged within these blocks. There were relatively
few structures of <1 Å RMSD, and therefore these were included in a <2 Å RMSD block.
Any of the 319 distorted complex structures resulting in an unphysical positive binding
affinity were excluded from the study, leaving 300 structures available for analysis.
The MM-GBSA binding affinities of the native complexes, their experimentally
determined binding affinities, and the MM-GBSA binding affinities of all distorted
protein-ligand complexes have been provided in the appendix A.
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RESULTS AND DISCUSSION
The results qualitatively suggest, as expected, that the lower the RMSD, the
higher chance of calculating a free energy of binding close to that calculated using the
native structure (figure 2.2). As the protein structures become more perturbed (higher
RMSD), the chance of calculating an accurate binding affinity decreases. For structures
of <2 Å RMSD from the crystal complex, the chance of correctly calculating the binding
free energy is usually highest among all the structures (between 10 and 28% error). For
the structures of >2 Å RMSD, the error in the free energy becomes more sensitive to the
structure of the protein and ligand (up to 44% error). Depending on how well new
contacts are compensating for lost native contacts, especially the hydrogen bond and
ionic pair contacts, the free energy of binding may or may not be close to the native
binding affinity after high structural distortion. The increasing variance in the calculated
percent errors of the binding affinities as a function of RMSD is primarily the result of
the increasing structural diversity represented in higher RMSD bins.
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Figure 2.2: Percent error in binding affinity upon structural distortion of all atoms of binding site
residues for all five systems studied. Zero RMSD corresponds to the native structure.
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1. Error in binding affinity generalized over all protein–ligand complexes
Previously, we have described the average percent error in binding affinity as a
function of structural error (RMSD) for five structurally diverse protein complexes. Now
we generalize these results by averaging over the individual protein complex results
(figure 2.3). In general, the error in the calculated binding affinity increases
monotonically with the error in binding site structure. Further, the standard deviations in
the binding affinity error generally increase with structural error, resulting from the
increased structural diversity represented in higher RMSD values, in some cases,
resulting in interactions that compensate for lost native interactions. For the structures of
<2 Å RMSD, the average percent error in calculated binding affinity is lowest with the
value of 14.78 (±7.5). For the structure with RMSD between 2–3 Å, 3–4 Å, and >4 Å, the
percent error in calculated free energy increases to 20.8 (±5.98), 22.79 (±11.3), and
29.43(±11.47), respectively.
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Figure 2.3: Percent error in binding affinity on structural distortion of binding site averaged over
the five diverse protein–ligand complexes studied.
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2. Role of ligand structure
Some further insight into the results can be gained by shifting the focus from the
protein structure to the chemical structure of the ligand. The ligands from the 1D7J and
2IFB complexes, both of which have one hydrogen bond donor and two hydrogen bond
acceptors, show a relatively steep change in the binding affinity error upon structural
distortion (figure 2.2). This can be explained by the fact that during the molecular
dynamics simulation, these ligands can adopt orientations in the restructured binding sites
that on average lower the binding affinity (figure 2.4). This favorable binding free energy
is partially due to the result of improved electrostatic interactions between the ligands and
the corresponding restructured binding sites (figure 2.5). In contrast, the ligands with
more hydrogen bond donors and acceptors (1LKK, 5CYH, 1FKF) show a weakening of
the average binding free energy upon restructuring of the binding site (figure 2.4).
The role of ligand structure in describing the error in calculated binding affinity
upon structural distortion of binding site can further be examined by observing the
direction of the change in binding free energy component. In order to get further insight
into role of ligand structure, we have calculated net change (G) within each block of
RMSD for the electrostatic (Coulombic and solvation) and van der Waals components
along with total binding free energy, along with calculating the absolute change in
binding free energy (|G|).
For 1D7J and 2IFB, which form relatively few hydrogen bonds or Coulombic
interactions with its ligand, the relatively steep change in the binding free energy upon
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structural distortion (figure 2.2) is primarily described by the favorable electrostatic
component of free energy (figure 2.5). Upon structural distortion of binding site, both
complexes show significant favorable change in Coulombic interactions with high
variance within each RMSD block. This demonstrates the possible structural
rearrangement of the ligands in the restructured binding pocket and thereby resulting in
more favorable interactions (figure 2.6). The solvation components of the free energy
show similar trend but in opposite direction along with high variance within each block
(figure 2.7).
The ligand of 1LKK, which has several hydrogen bond donors and acceptors
along with charged groups, shows significant unfavorable change in free energy of
binding upon structural distortion of the binding site (figure 2.4). This observation can be
attributed to the loss of the huge network of Coulombic interactions present in the native
complex that result mostly in the loss of binding affinity (figure 2.5, 2.6).
The 5CYH also shows a loss in Coulombic interactions upon structural
distortionof binding site. One difference is that the lost Coulombic interactions seem to
be significantly compensated by the more favorable solvation free energy. And therefore,
the total electrostatic component of free energy is relatively insensitive to the structural
distortion (figure 2.5). A similar phenomenon of compensation of columbic free energy
with solvation component of free energy can be observed with the 1FKF complex.
No considerable relationship was observed between ligand structures and change
in van der Waals components of free energy upon structural distortion (figure 2.8).
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However, there is significant change in van der Waals component upon structural
distortion. The solute entropic term and the solvent accessible surface area terms were
not found to show any significant change upon structural distortion.
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Figure 2.4: Percent change in binding affinity [%G] upon structural distortion of binding site
compared to the binding free energy of native complex.
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structural distortion of binding site compared to the electrostatic component of free energy of
native complex. [G(elec) = G(Coul) + G(GB)]
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native complex.
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CONCLUSIONS
The estimate of error in calculated binding affinities on structural distortion,
evaluated in this study, could be used while deciding on the utility of a particular
modeled structure, or as the selection criteria during the modeling process. This study and
other future studies provide a critical connection between the development of protein
structural models and their use in predicting and characterizing thermodynamic
properties. We believe that the results in this study will help researchers in assigning a
level of confidence for applications of modeled protein structures involving smallmolecule binding-affinity calculations.
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CHAPTER THREE

THE EVOLUTION OF CATALYTIC FUNCTION IN THE HIV-1 PROTEASE

ABSTRACT
The evolution of species is a complex phenomenon based on the optimization of a
multidimensional function referred to as the fitness. At the level of biomolecular
evolution, the fitness function can be reduced to include physiochemical properties
relevant to a particular molecule’s biological function. In this work, questions involving
the physical-chemical mechanisms underlying the evolution of HIV-1 protease are
addressed through molecular simulation and subsequent analysis of thermodynamic
properties related to the activity of the enzyme. Specifically, the impact of 40 single
amino acid mutations on the binding affinity toward the MA/CA (Ser-Gln-Asn-Tyr/ProIle-Val-Gln) substrate and corresponding transition state intermediate has been
characterized using a Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) approach. It is demonstrated that this approach is capable of extracting
statistically significant information relevant to experimentally determined catalytic
activities. Further, no correlation is observed between the effect of mutations on substrate
and transition state binding, suggesting independent evolutionary pathways toward
optimizing substrate specificity and catalytic activity. In addition, a detailed analysis of
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calculated binding affinity data suggests that ground-state destabilization (reduced
binding affinity for the substrate) could be a contributing factor in the evolutionary
optimization of HIV-1 protease. A numerical model is developed to demonstrate that
ground-state destabilization is a valid mechanism for activity optimization given the high
substrate concentrations experienced by the functional enzyme in-vivo.
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INTRODUCTION
The evolution of organisms can be described as occurring in the context of a fitness
landscape that maps genetic information onto phenotypic properties and their interaction
with the environment. One class of phenotypic property is the catalytic efficiency of
enzymes expressed within the species. Enzymes act to enhance the rate of biochemical
reactions and consequently are also critical in kinetically controlling the concentrations of
metabolic products within the organism. The catalytic activity of enzymes is therefore
inextricably linked to the survival of the organism and the propagation of the species. The
functional properties of enzymes evolve along with the organism in order to optimize the
specific metabolic functions of these organisms, thereby aiding in the ability of the
organism to adapt to its environment. The essential contribution of enzymes to the fitness
of an organism links the evolution of these molecules to the broader evolution of species.
In considering the HIV virus, the constituent enzyme HIV-1 protease is known to
play an essential role in the lifecycle of the pathogen. The enzyme catalyzes the
hydrolysis of specific peptide bonds releasing constituent proteins from the Gag and Pol
polyproteins during viral maturation to an infectious form [43]. Inhibition of this enzyme
is a key treatment strategy for halting the viral lifecycle and preventing the progression of
disease. Treatment of AIDS using protease inhibitors has further demonstrated that the
evolution of HIV-1 protease is closely linked to the survival of the HIV virus.
While the essential role of the protease makes it an attractive target for drug therapy,
the rapid replication rate (108-109 virions/day) of the virus, complemented by the high
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error rate of reverse transcriptase (about 1 in 10,000 base pairs), results in the rapid
accumulation and selection of drug resistant variants of the HIV-1 protease [43]. This
drug resistance process results in the selection of viral enzymes that avoid strong
interactions with drugs, but still maintain sufficient catalytic efficiency for the survival of
the virus. Drug resistance continues to be seen as one of the most challenging problems
resulting from molecular evolution.
Considering the important treatment implications of understanding the drug resistance
process in HIV-1 protease, numerous experimental studies have been performed on the
structure as well as the activity of different mutants. The availability of an extensive
amount of experimental information regarding various mutants makes HIV-1 protease an
excellent model system for the theoretical characterization of enzymatic evolution.
Development of a rationale describing the appearance of specific mutations in HIV-1
protease, with and without drug pressure has implications for improved inhibitor design
as well as giving fundamental insight into the mechanisms of enzyme evolution.
The characterization of physical mechanisms governing the effect of mutations on
the catalytic efficiency of HIV-1 protease can be considered as a step toward
understanding the molecular evolutionary process. From the perspective of molecular
modeling, this process involves modeling the reaction catalyzed by the enzyme and the
effect of a mutation on the catalytic process. The modeling of the reaction itself suggests
the need for quantum mechanical models that properly evaluate the energy changes
occurring during the bond breaking and forming process. However, modeling large
molecules over long (ns or longer) time scales typically requires the use of classical
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potentials. Considering these two competing factors, the QM/MM model has been
historically applied to the study of enzyme catalysis, successfully addressing the chemical
mechanisms associated with enzyme catalysis [44]. However, the extensive
computational time required for these QM/MM calculations constitutes a significant
challenge for studying a large number of mutations, which is often necessary while
characterizing broader evolutionary aspects of enzyme catalysis.
The use of classical molecular mechanics models to assess enzyme catalysis can fill
an important role in studying the evolution of enzyme function. Such models tend to be
computationally tractable for studying the effect of a large number of mutations on
enzyme activity. One of the classical approaches for studying enzyme catalysis involves
the consideration of a ground state model of the transition state, often described as a
transition state analogue [45]. These transition state analogue models can be used in the
context of a classical molecular mechanics protocol to evaluate the effect of mutations on
transition state binding. The transition state binding effects can then be used to describe
the effects on enzyme activity through transition state theory [46]. This reduces the
problem of estimating changes in activity to estimating the changes in binding affinity
upon mutation, a task suitable to classical molecular mechanics approaches. By using
computationally tractable classical models, it is possible to characterize larger portions of
the evolutionary landscape with the aim of identifying common physical mechanisms
underlying the process of enzyme evolution.
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The calculated activities obtained for different mutants in the current study were
compared to activity data determined using a bacteriophage lambda-based genetic screen
system that closely captures the in-vivo conditions associated with HIV-1 protease
function [47-49]. A statistically significant correlation between the calculated and
experimental activity data for HIV-1 protease was observed. In addition, analyses on 40
single amino acid mutants of HIV-1 protease indicate that most mutations, as expected,
destabilize transition state binding resulting in reduced activity. In addition, however,
most mutations appear also to enhance binding to the ground state, also resulting in
reduced activity as characterized through max. The enhancement of enzyme catalyzed
reaction rates through ground state destabilization is consistent with the MichaelisMenten mechanism under conditions where the substrate concentration is not
significantly smaller than KM. A numerical analysis of HIV-1 protease catalysis in the
immature viral particle environment suggests that the protease is acting and evolving
under such conditions. Further analyses also demonstrate that the impact of mutations on
ground state binding is only weakly correlated to the impact on transition state binding.
This decoupling of the effect of mutations may have implications for the evolvability of
enzyme catalysis.
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THEORETICAL BACKGROUND OF PROTEASE ACTIVITY CALCULATION
The complete equation describing the peptide hydrolysis reaction catalyzed by the
HIV1 protease can be written as

(3.1)
The above reaction can also be represented in terms of the free energy change with
respect to the reaction coordinate as shown in figure 3.1. Assuming that the activation
energy barrier of the first two steps is sufficiently low and the concentration of the active
conformer of the enzyme [E]0, which can form a complex with the substrate, is primarily
governed by the free energy difference between the folded, unfolded and dimer form of
enzyme, one can focus on steps 3, 4 and 5 of reaction 3.1 for the study of enzyme
catalysis. For these catalytic steps, the Michaelis-Menten formulation provides a widely
accepted quantitative description of enzyme catalysis [50, 51]. The rate of the reaction
(), according to the Michaelis-Menten formulation, can be given as:

 v =

k cat [ E ]0 [ S ]

K M + [S ]

KM =

where,

k cat + k −1
k1

The kcat, k-1 and k1 are the rate constants of the corresponding reaction steps.
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(3.2)

Figure 3.1: Profile of a peptide hydrolysis reaction catalyzed by the HIV-1 protease.
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A mutation in the HIV-1 protease potentially can have an effect on transition state
binding, substrate binding and/or the stability of the active conformer of the protein. In
the first case where a mutation affects transition state binding, the activation energy
barrier (G‡cat) and consequently kcat will be affected, which will affect the rate of the
corresponding reaction. In the second case, where a mutation affects substrate binding,
the effect on catalytic efficiency is highly dependent on the concentration of the substrate.
If the substrate concentration is low compared to the Michaelis constant (KM), the
concentration of the enzyme substrate complex will be governed by the reversible step 2
of reaction 3.1, and the change in substrate binding affinity will affect the forward and
reverse reaction rate constants (k-1 and kcat) by the same multiplicative factor

 − ΔΔG S
( exp
 RT


 ). Therefore, according to equation 3.2, this will have no affect on the


reaction rate. However, in the case of a high substrate concentration relative to KM, the
enzyme binding sites will be saturated by the substrate and therefore the reversible step 3
of reaction 3.1, describing substrate binding to the enzyme, becomes less significant. In
this case the effective rate equation can be written as
v = k cat [E ]0

(3.3)

Therefore, in the case of a high substrate concentration, a change in substrate binding
affinity upon mutation will directly affect the G‡cat and consequently the rate of the
reaction.
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According to equations 2 and 3, the change in the enzyme concentration caused by a
change in folding free energy or dimer stability will also result in a change in the catalytic
efficiency. In the present work, the binding affinity is calculated using a single trajectory
MM-PBSA method [52-54]. Using this technique facilitates the analysis of a large
number of mutations while primarily focusing on the affect of mutations on non-bonded
interactions between the enzyme and the substrate/transition state analogue. The effects
of mutations on monomer and dimer stability are not directly captured by the current
method.
The calculated binding affinity toward the transition state analogue (and substrate)
does not provide any direct information about the activation energy of the catalyzed
reaction; rather it provides information about the reduction in the activation energy
relative to the uncatalyzed reaction. For a general reaction, the activation energy of an
uncatalyzed reaction can be related to the free energy of the substrate state (GS) and
transition state (GT) as:
GTuncat - GSuncat =G‡uncat

(3.4)

And similarly for the catalyzed reaction,
GTcat - GScat =G‡cat

(3.5)

The difference in the activation energies of the catalyzed and unanalyzed reaction is
equivalent to the difference between the substrate and transition state binding free
energies.
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GT - GS = (GTcat – GTuncat) – (GScat - GSuncat)= G‡cat - G‡uncat

(3.6)

The binding affinity toward the substrate and transition state analogue therefore can be
directly related to the catalytic efficiency of the enzyme.
The same approach can be extended to the study of the effect of a mutation on the
catalytic efficiency of the enzyme, assuming the mutation does not significantly affect the
fold stability of the active enzyme. For an enzymatic reaction taking place at vmax, and
therefore at the effective rate constant of kcat, the effect of the mutation on the catalytic
efficiency can be described as

ν(wt) / ν(mut) = exp(-(G‡cat(wt) - G‡cat(mut))/RT)
= exp(-((GT(wt) - GS(wt)) – ( GT(mut) -GS(mut) ))/RT)

(3.7)

However, for a reaction taking place at a reduced substrate concentration as discussed
earlier, assuming the mutation does not affect the stability of the folded protein, the affect
of a mutation on substrate binding affinity is neglected and the reaction rate is primarily
affected by changes to the transition state binding affinity. Under these conditions, it may
be appropriate to calculate the effect of a mutation on the reaction rate using the
following expression:

ν(wt) / ν(mut) = exp(-( GT(wt) - GT(mut) )/RT)

(3.8)

As a result, the effects of mutations on enzyme activity can be ranked by changes in the
ground state / transition state energy gap (at higher substrate concentrations) or changes
in the transition state binding affinity (at lower substrate concentrations). In the current
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study, non-parametric correlations are determined between these energy changes and the
percent change in enzyme activity.
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METHODS
1. Modeling initial structures and molecular dynamics simulation:
The amino acid sequence of HIV-1 wild type protease was used as defined earlier
[55]. The initial coordinates of HIV-1 protease consistent with the wild type sequence
were taken from the crystal structure of an inhibitor bound complex at 1.80 Å resolution
(PDB ID: 1HXW.pdb) [56]. The structures of the MA/CA substrate and tetra-coordinated
water molecule were derived from another crystal structure of a catalytic aspartate
mutated (D25N) HIV-1 protease (PDB ID: 1KJ4.pdb) bound to MA/CA [57]. The
substrate and tetra coordinated water molecule were placed into the binding site of
1HXW by superimposing the backbone of its active site (residues with atoms within 4.5
Å of the ligand) on the corresponding atoms of 1KJ4 using CHARMM [36]. Another
water molecule was placed at the catalytic center based on interatomic distances at the
catalytic site determined in a previous study [58] (figure 3.2).
The model of the MA/CA transition state analogue was created in compliance with
the previously described tetrahedral anionic transition state [59]. This ground state model
of the transition state structure has been used successfully in the previous computational
studies of HIV-1 protease [60]. The catalytic site of the transition state analogue structure
was built using the information from the crystal structure of the tetrahedral intermediate
bound to HIV-1 protease [61] and the distances between heavy atoms were derived from
the crystal structure (figure 3.2). The protonation state of Asp was used as shown in the
figure 3.2.
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Figure 3.2: The key atomic distances at the catalytic site in (a) substrate bound structures and (b)
transition state bound structure used for modeling the initial structures. The distances are shown
in angstroms (Å).
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Amino acid point mutations were made to the wild type protease structure using the
protocol developed by Feyfant et. al. [62]. This algorithm uses MODELLER [63] to
predict the positions of the atoms in the new amino acid side chain using a knowledgebased scoring function and molecular dynamics simulation methods. The mutations were
made in the original inhibitor bound crystal structure (1HXW.pdb) before replacing the
inhibitor with substrate into binding pocket as described previously.
The atomic partial charges within the transition state analogue model were adopted
from similar atoms in the Charmm22 parameter [64] and from a previous study [59]. The
bond, angle, and dihedral parameters for the transition state analogue were also assigned
from similar chemical systems present in the Charmm22 parameter set.
All energy minimizations and molecular dynamics simulations were performed with
the molecular mechanics package CHARMM [36], using the 22nd version of the protein
force field [64]. A dielectric constant of 1 was used and the Lennard-Jones (L-J)
interaction was truncated beyond 10 Å using a switch function. The Particle-Mesh Ewald
(PME) method [65] was used to treat the electrostatic interaction with a 10 Å cutoff. A Bspline order of 4 and real space Gaussian width of 0.34 -1 was used in PME calculation.
The system was solvated in a truncated octahedron box of pre-equilibrated TIP3 water
molecules [66], and the distance between any atoms of the protein to the nearest face of
box was maintained to at least 10 Å. The system was neutralized and the salt
concentration was maintained close to 150 mM by adding KCl. The water molecules with
oxygen atoms closer than 2.6 Å to any atom of the solute were deleted. The bonds
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involving hydrogen atoms were constrained using SHAKE [67] in CHARMM. All
molecular dynamics simulations were performed in an NPT ensemble. The temperature
of the system was kept on average at 300K using the Nose-Hoover thermostat. The
constant pressure was maintained at 1 atm by the Langevin piston method [68]. Migration
of the solute protein outside the primary solvent box was discouraged during the
molecular dynamics simulation by a weak (0.5 kcal/mol) center-of-mass translational
restraint using the MMFP module [69] of CHARMM.
The systems (wild type and mutant HIV1 protease structures bound with substrate or
the transition state analogue) were first minimized for 500 steps using the steepest
descent (SD) algorithm, keeping solute atoms fixed in order to initially optimize the
solute interactions with water. In the next step, a distance based harmonic restraint was
applied between atoms at the catalytic site of the systems in order to restrain the distances
to values given in figure 3.2, with a high force constant (1000 kcal/mol/Å2). The system
was then minimized with the distance based harmonic restraints for 5000 steps using
Adopted basis Newton-Raphson (ABNR) algorithm keeping only both chains of the
protein fixed, allowing the substrate/transition state analogue and water molecule(s) to
optimize with respect to the binding pocket under the influence of the restraint. In
following steps, the distance based restraints were removed from the transition state
analogue bound structures but kept for substrate bound structures. The systems were then
minimized for 500 step using SD algorithm with harmonically restrained solute using a
force constant of 50 kcal/mol/Å2 followed by 100 steps of SD minimization with a force
constant of 10 kcal/mol/Å2 on the solute atoms.
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The force constant associated with distance based restraint in the substrate bound
structure was reduced to 200 kcal/molÅ2 before starting molecular dynamics, whereas no
distance-based restraints were present for transition state analogue bound structure at this
stage. The systems were gradually heated from 100K to 300K during 100 ps of
simulation, with a 1 fs time step and a center of mass translation restraint. All atom-based
restraints were then removed from the substrate bound structures, leaving only center-ofmass restraints on the systems (both on substrate bound and transition state bound
structures). The molecular dynamics simulation in an NPT ensemble at a temperature of
300K was performed for equilibration (2-7 ns) and production (2 ns), using a 2 fs time
step. Most of the structures were equilibrated within the initial 2 ns equilibration
simulation after heating, however, for a few mutant systems the equilibration time was
extended to 7 ns.
2. MM-PBSA and entropy calculations
Binding affinities were calculated using the MM-PBSA method. According to the
MM-PBSA protocol, the binding affinity of a ligand to its receptor can be estimated by
calculating the average change in gas phase energy Ugas, the average change in the
solvation free energy Gsolv and the average change in the conformational entropy
contribution to the binding –TS (17-19). In the present study, the free energy changes
were estimated from single trajectories of protein-ligand complexes (single trajectory
MM-PBSA) [52-54]. The flap motion in HIV1 protease is a relatively long time scale
motion and therefore unbound protease cannot be accurately sampled with relatively
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short (nanosecond time scale) simulations in explicit solvent [53, 70]. This is the primary
reason to choose a single simulation MM-PBSA method over the frequently used three
simulation MM-PBSA calculation in which separate simulation trajectories of protein,
ligand and complex are used for free energy estimation. The single trajectory MM-PBSA
calculation method has been successfully used with the HIV1 protease in previous studies
[70, 71].
The gas phase energy (Ugas) in the single trajectory MM-PBSA calculation includes
Coulombic energy (Gcoul) and van der Waals energy (GvdW). The gas phase energies were
calculated from molecular mechanical energy function using Charmm22 [64] parameters.
An internal dielectric constant of 4 and no cutoff was used while evaluating the MM
energies.

ΔGbind = Gcomplex − Greceptor − Gligand
G MM − PBSA = U gas + G solv − T S ,

The polar part of the solvation energies (Gsolv-pol) was calculated using the PoissonBoltzmann (PB) equation.

The PBEQ module of Charmm was used to calculate

electrostatic solvation free energy. The dielectric interface defined from the molecular
(contact and reentrant) surface and a grid spacing of 0.4 Å was used. An internal
dielectric constant of 4 and solvent dielectric constant of 80 was used in the PB
calculation.
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The non-polar part of solvation (GSA) energy was calculated using the solvent
accessible surface area method, where the solvent accessible surface area (SASA) was
calculated using a probe radius of 1.4 Å.

Gnp = SASA + b
The values of 0.00542 kcal/mol-1/ for surface tension coefficient , and 0.92 kcal/mol
for offset b were used as suggested previously [72].
The change in entropy estimation was performed using the VIBRAN module [73] of
CHARMM, with the snapshots extracted every 40 ps from the production run. The
normal mode analysis of the protein, ligand and protein-ligand complexes was performed
in order to estimate the vibrational contribution to the change in entropy upon ligand
binding. A distance dependent dielectric with definition of 4r was used while doing the
normal mode calculations, where r is the pairwise distance between atoms. The
electrostatic interaction was truncated beyond 12 Å using shift function. The loss of
transitional and rotational degrees of freedom upon protein ligand binding was estimated
from the mass and moment of inertia of the protein [74], ligand and protein-ligand
complex evaluated within the VIBRAN module of CHARMM.
In calculating the Spearman correlation, the lowest rank was assigned to the mutant
with the lowest experimental activity and the higher rank to the greater experimental
activity. Similarly with the calculated activity, the lowest rank was assigned to the lowest
calculated activity and higher rank to the larger calculated activity. The Spearman
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correlation () between the experimental rank (xi) and the calculated rank (yi) was
calculated as
_

ρ=

_

i( xi − x)( yi − y)
_

_

 ( x − x) ( y − y )
i

2

2

i

i

P-values associated with the correlation coefficients were determined using the two-tailed
test based on the t-distribution.
The ability of the MM-PBSA method in estimating the absolute binding affinity has
been questioned [53]. However, the MM-PBSA method has been successfully used in
predicting relative binding affinities (25, 26). Based on this, a Spearman correlation was
chosen to address the statistical relationship between the experimental and calculated
activities.

49


RESULTS AND DISCUSSIONS
1. Rank correlation to the experimental data:
The rank correlation between the calculated activities and the experimental activities
were determined for 12 systems (G17E, M36V, N37S, G40E, K43R, M46V, M46T,
G48E, L63P, L63V, N88D and wild type structure), available from a random
mutagenesis activity analysis of the HIV-1 protease [47]. The calculated change in
activation energy based on the change in substrate or ground state (GS) binding and
transition state (TS) binding (using equation 3.7) show a strong and statistically
significant Spearman correlation (r=0.81, r2=0.66, p=0.001) with the experimental
activity (figure 3.3). These results suggest that the affinity between the enzyme and both
the transition state and the ground state substrate are factors for activity manipulation
during course of evolution in HIV-1 protease. The MM-PBSA energies for the wild-type
and each mutant are given in the appendix B.
The correlation between experimental order of activity and the calculated activity is
not significantly reduced (r=0.74, r2=0.55, p=0.005, figure 3.4) if only the change in
transition state binding free energy is considered for the activity estimation (using
equation 3.8). Mathematically, this is because the variance in TS binding due to the
mutation (29.05 kcal/mol) is an order of magnitude larger than the variance in the GS
binding (2.37 kcal/mol) for the mutants used in the experimental comparison. Physically,
the larger variance in TS binding upon mutation is consistent with its larger average
binding free energy. Stronger binding affinity towards the transition state relative to the
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substrate is expected because of the strong electrostatic interaction between transition
state stabilizing residues in the enzyme and the transition state [75]. The change in
transition state binding affinity appears to be a major cause of the change in activity
resulting from mutation. However, as discussed previously, the in-vivo substrate
concentrations experienced by HIV-1 protease suggest that substrate binding is also
likely to contribute toward the catalytic activity of the enzyme.
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Figure 3.3: The rank correlation between experimental and predicted rank of activity considering
substrate binding along with transition state binding for activity calculation.
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Figure 3.4: The rank correlation between experimental and predicted rank of activity considering
only transition state binding for activity calculation.
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Further analysis of the binding free energy components can provide more insight into
role of electrostatic interactions. On comparing the components of the free energy of
binding for the substrate and transition state, the relatively strong affinity for the
transition state compared to the substrate arises primarily through electrostatic
interactions (table AB1 in appendix B). Therefore, the electrostatic affinity toward the
transition state distinguishes its binding mechanism from that of the substrate. Looking
further into the components of the binding free energy, the change in calculated activity
considering both the substrate and the transition state binding (equation 3.7) is mostly
described by the change in the electrostatic component of transition state binding affinity
(table 3.1). The significant contribution of electrostatic interactions toward the
stabilization of transition states in enzymes has been demonstrated numerous times [7678]. In addition, these results are also consistent with a recent study [60] where the
electrostatic interactions with the transition state were shown to be key factors in
predicting drug resistant mutations in HIV-1 protease.
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Table 3.1: MM-PBSA free energy decomposition describing the effects of 11 single amino acid
mutants on substrate and transition state binding affinity as well as the change in activation
energy (Gactive=Gt-Gs).

Free energy term

Average change in
substrate binding
(Gs)
-6.27(1.57)

Average change in
transition state
binding (Gt)
5.49(5.39)

Average change
in Gactive

-1.91(1.92)

4.02(6.81)

5.93(8.01)

van der Waals (GvdW)

-0.06(2.35)

0.24(2.87)

0.31(3.025)

Coulomb (Gcoul)

-2.95(4.00)

3.60(7.36)

6.55(9.32)

Polar Solvation (Gpol-solv)

0.95(3.77)

0.21(2.69)

-0.74(4.29)

Electrostatic (Gelec)

-1.99(2.12)

3.81(6.32)

5.81(6.16)

Chain Entropy (TS)

4.35(2.27)

-1.47(2.39)

-5.83(3.58)

Total Free energy
Total enthalpy (H)

Numbers in parentheses are standard deviations associated with averages.
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11.77(5.44)

In the present study, a simple and computationally tractable classical model approach
has been shown to capture a significant portion of the information relevant to changes in
enzyme activity. Using an endpoint free energy calculation method (MM-PBSA), it is
possible to qualitatively predict the relative activity of 11 mutants and the wild type HIV1 protease. Prior work has demonstrated the utility of classical methods for assessing the
effects of mutations on the function of enzymes [46, 79]. For instance, it has been shown
recently that classical techniques for evaluating TS binding are capable of predicting the
emergence of specific mutations in HIV-1 protease in response to drug treatment [60].
While the availability of experimental data suggests HIV-1 protease as a favorable
model system for the study of enzyme evolution, the low stability of the enzyme presents
challenges. HIV-1 protease has a stability of ~2.2 kcal/mol [80], suggesting that a greater
fraction of random single amino acid mutations may significantly disrupt the structure.
This is consistent with the experimental observation that 2/3 of random mutations in
HIV-1 protease result in an over 90% loss of activity [47]. The typical limitations of fully
atomic molecular mechanics studies to ns timescale simulations limit the ability to detect
changes in binding affinity that result in part from significant conformational changes in
mutant enzymes. These limitations were exemplified by analyzing mutations in sequence
positions 50-57, which are known to disrupt the structure of HIV-1 protease.
The Spearman correlation between the activities determined from experiment and
those determined from calculations decreases significantly (r2=0.19, p=0.16 using
equation 3.7 and r2=0.21, p=0.13 using equation 3.8) when considering mutations in
positions 50-57 (I50V, F53L, I54V, R57S and R57G). Mutations at positions 50, 53 and
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54 have been shown to affect the stability of the active form of HIV-1 protease [81, 82].
In addition, the side chain of R57 has been shown to form several important contacts
within the protease [83-85] consistent with this residue being important for fold stability.
Substitutions at this position with a smaller side chain, which cannot compensate for the
lost hydrogen bonds and salt-bridges, can have an adverse affect on the stability of the
protease. This may also partly explain the existence of R57K as the only significant
polymorphism of position R57 in HIV-1 protease [55]. This evidence suggests that some
mutations act to disrupt the stability of the well-characterized folded conformation of
HIV-1 protease leading to reduced activities. These instances will present challenges to
traditional computational techniques for charactering the effect of random mutations on
binding free energy and catalytic activity.
2. Statistical analyses of 40 mutants on calculated activity
While some approximations are clearly inherent to any modeling approach, statistical
analyses of a broader dataset can provide information that is more robust than an
individual measurement. In order to more broadly assess the physical mechanisms
underlying the effect of mutations on enzyme activity, the study was expanded to include
29 additional mutations that were found in a population of untreated patients based on an
analysis of the HIV-1 protease sequence database from the Stanford University HIV drug
resistance database [55]. Therefore in examining these mutations, naturally occurring
polymorphisms are studied that are also less likely to result in a significant destabilization
of the native fold and the subsequent loss of all catalytic activity. In other words, these
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mutations are likely to be both relevant to the natural evolution of the enzyme and
amenable to the analysis performed in this work.
More insight into the binding mechanisms of the substrate and transition state
analogue can be gained through analyses of the free energy components. As discussed
earlier, the binding enthalpy to the transition state is more favorable than binding to the
ground state primarily due to the electrostatic component (table 3.2). This is followed by
some compensation in –TdS, since the stronger MM-PBSA energy is compensated by a
weaker –TdS contribution to binding affinity (table 3.2). The mutations in general tend to
weaken binding affinity to the transition state (figure 3.5). This appears to happen
through a combination of energy terms. The most significant contributor appears to be the
electrostatic component of the binding free energy (75% of mutants show weakened
affinity in this term with an average change of 1.84 kcal/mol for all 40 mutants) and the
binding entropy contribution, -TdS (87.5% of mutants show weakened affinity with an
average change of 1.7 kcal/mol) as shown in table 3.2. The van der Waals term also
appears to play some role with 57% of mutants showing weaker binding through this
term resulting in an average change of 0.8 kcal/mol.
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Table 3.2: Impact of 40 HIV-1 protease mutations on substrate and transition state binding.
Free energy term

Percent of mutations stabilizing
substrate binding

Percent of mutation
destabilizing transition state
binding

Total (H)

100

80

van der Waals (GvdW)

42.5

60

Coulomb (Gcoul)

80

45

Polar Solvation (Gpol-solv)

50

75

Electrostatic (Gelec)

90

75

Chain Entropy (TS)

95

87.5

Average change in substrate
binding

Average change in
transition state binding

Total (H)

-6.79(2.69)

4.37(5.17)

van der Waals (GvdW)

-0.01(3.10)

0.89(2.83)

Coulomb (Gcoul)

-3.06(3.49)

0.09(5.59)

Polar Solvation (Gpol-solv)

0.20(4.00)

1.74(2.59)

Electrostatic (Gelec)

-2.85(1.98)

1.84(4.41)

Chain Entropy (TS)

4.09(2.11)

-1.7(1.86)

Nmbers in parentheses are standard deviations associated with averages.
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Mutations also result in an increase in binding affinity toward the substrate (figure
3.5). The increase in binding affinity for the MA/CA upon random mutation suggests that
HIV-1 protease has evolved to bind less tightly to this substrate. This observation is
further supported by the fact that enzymes in general have not evolved to bind the ground
state (substrate) very tightly [75, 86, 87]. This could further be a consequence of the fact
that HIV-1 protease is a promiscuous enzyme that is known to catalyze the hydrolysis of
multiple sequences within the Gag-pol polyprotein. Weak binding toward any one
substrate may be a consequence of frustration in evolving promiscuous activity. This
weaker binding toward the substrates may also impact the protease’s catalytic efficiency
as this enzyme is likely acting in a high substrate concentration environment. Under high
substrate concentrations, weakened binding to the substrate (ground state destabilization)
can theoretically result in a lower activation barrier and an increased catalytic rate [88].
An increase in the electrostatic component of the binding free energy is the major
contributor (an average of -2.85 kcal/mol for all 40 mutants) toward the increase in
substrate binding affinity for most (90%) of the mutations. The entropic term also plays a
significant role in discriminating the effect of mutations on substrate and transition state
binding. 95% of mutations show improved binding affinity toward the substrate with an
average of -4.09 kcal/mol through entropic term (table 3.2), for all 40 mutants. As
discussed earlier, these factors affecting ground state stabilization, along with transition
state destabilization, could have direct implications for protease evolution by affecting
the reaction rate.
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Figure 3.5: (a). The change in binding affinity toward the transition state for different mutants
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relative to the wild type; (b). The change in binding affinity toward the substrate for different

mutants relative to the wild type.
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3. Relation between change in substrate binding and transition state binding upon
mutations
The correlation between the calculated change in substrate and transition state
binding for the 11 mutants that have been compared to experiment, as well as the larger
set of 40 mutants, were determined. If the effects of mutation on substrate binding and
transition state binding were highly correlated with some significant slope, mutations
would have an attenuated effect on the previously mentioned energy gap and
consequently a weaker effect on kcat and max. The lack of correlation (figure 3.6)
indicates the evolution of the affinity to the ground state substrate and transition states are
independent, possibly resulting in faster evolution of kcat or max.
The weak correlation between a change in substrate binding and transition state
binding upon mutation could also have implications in evolving activity and specificity
independently. When considering moderate or low substrate concentrations, the catalytic
rate is determined by the kcat /KM. Under these conditions, the effective rate constant is
insensitive toward changes in substrate binding affinity while remaining sensitive toward
changes in transition state binding affinity. Alternatively, the specificity of the enzyme
towards particular substrates can primarily be determined through substrate affinity [89].
Therefore, the ability to evolve ground state binding affinity and affinity towards the
transition state independently through different mutations could also lead to the efficient
and independent evolution of enzyme activity and enzyme specificity.
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Figure 3.6: The relationship between substrate binding and transition state binding upon
mutations in HIV-1 protease. (a). Change in substrate binding affinity vs. change in transition
state binding affinity compared to wild type for 12 variants used for comparison with experiment.
(b). Change in substrate binding affinity vs. change in transition state binding affinity for 40 HIV1 protease variants. (c). Rank correlation of substrate binding affinity vs. transition state binding
affinity for 12 variants used for comparison with experiment. (d). Correlation between substrate
binding free energy and transition state binding free energy for 40 variants of HIV-1 protease.
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4. Numerical model for HIV-1 protease catalytic process:
Affinity calculations described here suggest that mutations in the wild-type HIV-1
protease generally reduce the affinity toward the transition state or alternatively enhance
the affinity toward the substrate. Posing this observation from the evolutionary
perspective of mutations that lead to the wild-type, the calculations suggest that in the last
stages of the evolution of HIV-1 protease, mutations may strengthen binding to the
transition state or reduce the affinity toward the substrate. As described earlier, the
strengthened binding toward the transition state can lead to enhanced activity by directly
lowering the activation energy barrier.

However, based on the Michaelis-Menten

mechanism, the effect of weakened substrate affinity on enzyme activity is dependent on
the local substrate concentrations. In order to correctly rationalize the catalytic
mechanism of HIV-1 protease under physiological conditions, a numerical solution to the
Michaelis-Menten equation is derived using experimentally determined parameters
associated with the activity of HIV-1 protease. The numerical model suggests that the
concentration of the substrate in the immature virus particle (prior to activation of the
protease) is significantly higher than KM and supports the theory that ground state
destabilization could be a viable evolutionary mechanism for manipulating the activity of
this enzyme.
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Figure 3.7: Relationship between substrate concentration, change in substrate binding affinity and
catalytic rate of the enzyme (on z-axis).
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The reaction 3.1 can also be rewritten as:

(3.9)
In this model, a mechanism was proposed that incorporates the characteristic flap motion
of HIV-1 protease. The flaps within the HIV-1 protease are known to adopt different
conformations depending on whether the enzyme is bound or unbound. In the current
kinetic model, the opening and closing of the flaps in the apo state is assumed to establish
a prior equilibrium before binding the substrate. The remaining mechanism follows the
traditional Michaelis-Menten model where a steady-state concentration is assumed for the
enzyme/transition state complex. The equilibrium constant of the flap (Kflap) was
estimated to be 7.9X10-6, considering the free energy change of 7 kcal/mol upon flap
closing based on a potential of mean force calculation [90]. Assuming the transition state
barrier for substrate binding and unbinding to be 10 kcal/mol and 5 kcal/mol respectively,
the rate constant for the substrate binding (k1) and unbinding (k-1) was calculated to be
11303.96/Ms and 2.57/s respectively. The calculated rate constant k1 and k2 are found to
be consistent to that estimated from NMR experiments, which suggest that k1 should be
less than 20,000/Ms and k-1 should be a maximum of 10/s [91]. Therefore, in the current
analysis, the simplified model of the substrate binding mechanism provides a reasonably
good estimate of the rate constants for substrate binding. The calculated dissociation
constant (Kd) using the present model was calculated to be 0.22 mM, which is in
excellent agreement with another experimental observation that suggests the Kd should be
approximately 0.2 mM [91]. Considering the activation energy of the reaction to be 18
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kcal/mol [92], the kcat is estimated to be 0.48/s, also in agreement with experiment [93].
Therefore the KM turns out to be 0.27 mM, which is consistent with the suggested range
of 0.01-0.5 mM [93]. Considering these calculated parameters, figure 3.7 demonstrates
the relationship between the substrate concentration, the change in substrate binding
affinity and the turnover rate for a standard 1 M enzyme concentration. The concentration
of the enzyme will vary as virus matures; however, the value of enzyme concentration
will affect the rate of the cleavage, but will not affect the relationship toward the ground
state (substrate) binding affinity.
Figure 3.7 indicates that at low substrate concentrations, as expected, changes in the
ground state substrate binding affinity do not change the rate of the reaction. However,
within a 100 nm diameter immature viral particle [94] comprised of 1500 gag and gagpol precursor molecules [95] (each of which contains at least 12 substrate cleavage sites)
the concentration of only the MA/CA site described here is estimated to be approximately
4.7 mM (higher than KM). At this substrate concentration, the figure 3.7 shows that
changes in the substrate affinity can have a significant effect on the catalytic rate. This
simplistic model suggests that ground state destabilization is a plausible physical
mechanism contributing to the evolution of HIV-1 protease activity within the
environment of the immature HIV-1 viral particle.
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CONCLUSIONS
In the current manuscript, we have further demonstrated the potential of classical
force fields in predicting enzyme activity by estimating the relative activities of a
statistically significant number of HIV-1 protease mutants. In addition, we have
attempted to further characterize the role of substrate binding during the evolutionary
process of this important disease target. The significant correlation between the predicted
activity and the experimental activity along with the numerical model developed to
describe the activity of HIV-1 protease suggests that substrate binding could be a
determining factor in manipulating enzyme activity during the evolution of HIV-1
protease. We suggest that this ground state destabilization in the wild-type HIV-1
protease can lead to enhanced catalytic efficiency in the high substrate concentration
environment within the immature viral capsid. We further observed that changes in
substrate binding and transition state binding due to mutation are not correlated. As
discussed earlier, this could have implications in rapidly optimizing vmax and in more
effectively evolving both enzyme specificity and catalytic efficiency.
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CHAPTER FOUR

ROLE OF DYNAMICS AS A CONSTRAINT ON THE EVOLUTION OF
HIV-1 PROTEASE

ABSTRACT
The characteristic low frequency motions (dynamics) of an enzyme have been
proposed to be critical for its catalytic efficiency. It has also been proposed that
mutations, which disrupt the dynamics of an enzyme, could adversely affect its catalytic
efficiency. Since the deleterious effects of mutations on the functional property of an
enzyme can impose a significant constraint on its evolution, the present study examines
the role of dynamics as a constraint on the evolution of HIV-1 protease. HIV-1 protease
is a key target for AIDS therapy, and therefore, identification and characterization of
constraints on its evolution is necessary for predicting drug resistant mutations. In present
study, we are testing the hypothesis that sequence positions participating in correlated
motions will result in substantially reduced catalytic activity in the HIV-1 protease when
these positions are mutated. Testing this hypothesis will provide information related to
the functional importance of correlated motions in HIV-1 protease activity and
consequently whether the preservation of correlated motions is a constraint on its
evolution. We have studied the role of dynamics as the constraint on the evolution of
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HIV-1 protease by identifying highly correlated positions from molecular dynamics
simulation, and comparing it to experimental activities of mutants at these positions. Our
analysis was unable to identify any significant constraint that dynamics imposes on the
evolution of HIV-1 protease. Consequently, explicit knowledge of dynamical features
related to the catalytic property of HIV-1 protease doesn’t appear to be necessary for the
prediction of drug resistant mutations.
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INTRODUCTION

The human immunodeficiency virus type 1 (HIV-1) protease is a virally encoded
enzyme that catalyzes the cleavage of Gag and Gag-Pol poly proteins of the immature
AIDS virus, and therefore plays an important role in its maturation process[16]. Due to its
key role in the viral reproduction cycle, HIV-1 protease has been one of the major targets
in AIDS treatment[96]. However, due to the inefficient replication process of HIV-1
virus, different mutational variants of HIV-1 protease are rapidly produced and
selected[5]. Some of these mutational variants result in resistance against protease
inhibitors and are therefore preferably selected in the presence of drug. This process of
selecting different mutational variants of HIV-1 protease can also be looked as enzymatic
evolution.
The evolutionary pathways and outcomes of an enzyme are significantly regulated
by the constraints imposed from deleterious effects of amino acid mutations on functional
properties. And therefore, identification and characterization of these evolutionary
constraints is critical for prediction of evolutionary pathways and outcomes (including
drug resistant mutations in the case of HIV-1 protease).

Recent experimental and

theoretical studies suggest that the characteristic low frequency motions (dynamics) of
enzymes are evolutionarily selected features that contribute to the catalytic activity of an
enzyme[17, 18, 97, 98]. It has been further suggested that mutations that alter the
dynamics of an enzyme could have deleterious effects on its catalytic activity[99], and
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therefore dynamics can act as the constraint on its evolution. However, the role of
dynamics as a constraint on the evolution of HIV-1 protease has not been well
characterized.
Collective low frequency motions are inherent and characteristic to any protein
structure[100]. These collective low frequency motions are often connected to low
frequency normal modes and broadly termed as dynamics[101]. Since structure of an
enzyme is well-known to be critical to its function and dynamics also follow from the
structure, the protein dynamics has been thought to be an important factor in describing
the enzyme function[100, 102]. Several NMR and theoretical studies have proposed the
protein dynamics to be a determinant factor in molecular recognition, allosteric
regulation, and enzyme catalysis[103-108]. More discussion about dynamical effect on
the enzyme catalysis can be found elsewhere[98, 109, 110].
One way to computationally characterize the effect of low frequency motions on
enzyme activity has been the analyses of the covariance of displacement of residues
within an enzyme[107]. Nanosecond (ns) time scale molecular dynamics simulations
have been shown to capture most of the relevant correlated motions of the residues,
including those identified from low frequency harmonic motions[111]. Therefore,
analyzing the correlated motions of the residues from molecular dynamics trajectories has
been in frequent practice to study the role of protein dynamics[112-117]. From the
linearly correlated motions observed in molecular dynamics simulations, significantly
positively correlated motions can result from long range coupling within the protein, but
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can also be a side-effect of the neighboring secondary structures. However, most of the
highly negatively correlated motions are not the result of a trivial relationship between
residues, and therefore have been hypothesized to be important dynamic features linked
to enzyme activity[107]. It has been suggested that non-trivial correlated motions are
evolutionary selected features that are important for enzyme function, and mutations in
these negatively correlated regions can disrupt the enzyme function[107]. In further
studies, it was postulated that a change in correlated motion caused by a mutation in any
region of protein is related to a change in functional properties. Therefore change in
linear correlation was considered as a parameter to address the effect of mutation on the
function of any enzyme[118].
In the present study, we have examined the role of dynamics as a constraint on the
evolution of HIV-1 protease. Since the theoretical background of the dynamical effect on
the catalytic efficiency is not very well established, one of the best approaches to study
the role of dynamics is to examine its relationship with experimental mutant activities.
This has been accomplished by studying the HIV-1 protease bound with one of its natural
substrate (MA/CA). The experimental data published by Martinez et. al.[47], where the
effect of 98 mutations on the catalytic activity of HIV-1 protease toward its natural
peptide substrate (MA/CA) has been determined, was used in conjunction with recently
determined structures of HIV-1 protease bound to peptide substrates[57] and correlated
motions within the relevant Michaelis complex were analyzed. The abundance of
experimental information complemented with detailed molecular modeling makes
possible a statistically significant study of the effect of correlated motions on enzyme
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activity. In brief, the evolutionary importance of the positions possessing significant
correlation has been examined by analyzing the experimental information about
mutations at these positions and by comparing it with the experimental information about
the mutations at different region of protein.
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METHODS

1. Structure modeling and molecular dynamics simulation:

The models of HIV-1 protease and MA/CA substrate complex were prepared
using following methodology. The structures of the substrate MA/CA and tetra
coordinated water molecule were derived from a crystal structure (PDB id: 1KJ4)[57] and
placed into the binding pocket of another HIV-1 protease structure (PDB id: 1HXW)[56]
that has an amino acid sequence consistent with the wild type definition[55]. The ligand
and water were placed into the binding pocket of 1HXW by superimposing the backbone
atoms of its active site residues (within 4.5 Å of ligand) on the corresponding atoms of
1KJ4. Another water molecule was placed at the catalytic site using inter atomic
distances from previous study[58] (figure 4.1). The modeled mutant structures were
generated using tools within MODELLER[63], as suggested by Feyfant et. al.[62].
The energy minimization and molecular dynamics simulation of different
structures were performed with the molecular mechanics package CHARMM[36], with
its 22nd version of force field[64]. The Particle-Mesh Ewald (PME) method was used to
treat the electrostatic interaction with a dielectric constant of 1 and a cutoff of 10 Å. A Bspline order of 4 and real space Gaussian width of 0.34 A-1 was used while performing
PME calculations. The Lennard-Jones interactions were switched to zero beyond 10 Å.
The structures were solvated in a truncated octahedron box of pre-equilibrated TIP3P
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water molecules[66], with a minimum distance of 10 Å from any face of the box to any
atom of solute. The salt concentration of the solvated system was maintained close to
150mM by adding KCl ions, while keeping total charge of resulting system at zero. Any
water molecules with their oxygen atom closer than 2.6 Å from any atoms of solute were
removed from the system. Covalent bonds involving hydrogen atoms were constrained
using SHAKE[67] during energy minimizations and molecular dynamics (MD)
simulations. MD simulations were performed in the NPT ensemble, where temperature
was maintained to an average of 300K using the Nose-Hoover thermostat and pressure
was maintained to 1atm using the Langevin piston method[68]. The position of the
Michaelis complex was restricted within the primary solvent box by a weak (0.5
kcal/mol/Å2) center of mass translational restraint using the MMFP[69] module of
CHARMM.
The systems were first minimized for 500 steps using a steepest descent
algorithm, keeping solute atoms fixed. Next, a distance based restraint between atoms at
the catalytic site was applied with a force constant of 1000 kcal/mol/ Å2 (figure 4.1). The
system was then minimized for 5000 steps using an adopted basis Newton-Raphson
(ABNR) algorithm and both segments of protein were kept fixed in order to optimize the
substrate interactions with the protein. At this stage, the distance based restraints were
removed from the transition state bound structure, but kept for the substrate bound
structure. The solute atoms were then harmonically restrained with a force constant of 50
kcal/mol/Å2 and minimized for 500 steps using the SD algorithm, followed by 100 steps
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of SD minimization with a reduced force constant of 10 kcal/mol/Å2, keeping the
distance based restraint for the substrate bound structures only.
The force constant of the distance based restraint in substrate bound structures
was reduced to 200 kcal/mol/Å2, and the system was gradually heated from 100K to
300K during 100 ps of MD simulation. A 1fs time step was used during heating. In
following steps, all atom based restraints were removed and the MD simulation of the
system was performed for a further 2-7ns (equilibration time was different for different
structures) for equilibration. Subsequently, a production simulation of 2ns for mutant and
8ns for wild type structures was also performed for the analysis.
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Figure 4.1: The key inter atomic distances at catalytic site in MA/CA bound HIV-1
protease. The distances are given in (Å)
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2. Covariance analysis and comparison to experiment:

The linearly correlated motions (linear correlation C(i,j)) between each sequence
position are calculated with respect to the alpha carbons of individual amino acids as
described by equation 4.1, using CHARMM.

C (i , j ) =

< Δri ⋅ Δr j >
< Δri 2 >1 / 2 < Δr j2 >1 / 2

(4.1)

Here, ri and rj are the displacement vectors for the atoms i and j, and the angle brackets
denotes an ensemble average.
Amino acid positions were then grouped based on the largest magnitude negative
correlation observed for that amino acid position. Then the effect of mutations within this
group of sequence positions on the activity of the enzyme (based on experimental
measurements) was compared to the (average) effect of mutations on all positions. The
goal here is to test the hypothesis that positions exhibiting negatively correlated motions
are critical for enzyme function, and as a result these positions when mutated should
result in more dramatic losses of enzyme activity than mutations elsewhere in the
sequence. If the average effect of mutations on the negatively correlated group was more
dramatic than that observed on average for all positions, then this would be evidence
supporting the hypothesis that negatively correlated amino acid positions are particularly
critical for enzyme function. The impact of mutations on a group of amino acid positions
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was determined by identifying the fraction of positions in the group that reduce the
activity of the enzyme by 90% or more following a mutation based on experimentally
collected data (“zero” activity positions).
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RESULTS AND DISCUSSION

Given that it is unclear exactly what degree of dynamic anti-correlation would
constitute a cutoff for dynamical effects, a range of different values were examined from
-0.19 to the maximum identified negative correlation (-0.37). The positions were grouped
based on correlation coefficient and the fraction of “zero” activity positions were
determined in each group. The group identified as any residue having an anti-correlation
with some other position of  -0.19 contained all positions in our experimental dataset.
Based on figure 4.2, we see that there is no steady increase in the fraction of
“zero” activity positions as we focus on more negative correlation in motion. Moving
from right to left in figure 4.2, we see no clear trend demonstrating that more negative
correlated positions become more sensitive toward mutation. We further generated two
groups of amino acid positions based on the wild-type correlated motion map. The first
group (group 1) corresponds to amino acid positions that exhibit the strongest negatively
correlated motions. The second group (group 2) of amino acid positions exhibits the
weakest negatively correlated motions. The objective was to compare the effect of
mutations within each group of amino acid positions on the activity of the enzyme to see
if there was any significant difference between the two groups. The standard hypothesis
would be that amino acid positions exhibiting the strongest negatively correlated motions
(group 1) would exhibit the largest changes in activity upon mutation (since these
positions are hypothesized to be critical for the function of the enzyme). The results seen
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in table 4.1 indicate that, the amino acid positions that show the most negatively
correlated motions are not more sensitive toward mutation in comparison to positions that
show very little negatively correlated motion.
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Fraction of Positions with Zero Activity Mutants

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

-0.38 -0.36 -0.34 -0.32 -0.3 -0.28 -0.26 -0.24 -0.22 -0.2 -0.18
Maximum Negative Correlation

Figure 4.2: The relationship between the negative correlation coefficient and fraction of
corresponding positions showing loss of activity upon mutation.
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Table 4.1: Summary of catalytic activities within correlation coefficient groups.
Correlation
coefficient(Cij)

Number of
total
positions in
group

Number of
position
studied in
experiment

Number of positions
with “zero” activity

Fraction of position
that upon mutation
result in 10% of
wild type activity
as observed in
experiment

Group
1

Cij<-0.31

28

22

16

73

Group
2

-0.26Cij

35

22

16

73
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In addition, we examined whether residues exhibiting positively correlated
motions could be linked to the activity of the HIV-1 protease. Similarly, no significant
trend is observed between the degree of positive correlation exhibited by an amino acid
position and the impact on the activity resulting from mutating that position. In figure
4.3, as we consider amino acids that have greater positively correlated motions, there is
no trend demonstrating increase in the fraction of mutations that adversely affect the
activity of the enzyme.
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Fraction of Positions with Zero Activity Mutants

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

0.25

0.3

0.35

0.4 0.45 0.5 0.55 0.6
Maximum Positive Correlation

0.65

0.7

0.75

Figure 4.3: The relationship between the positively correlation coefficient and fraction of
corresponding positions showing loss of activity upon mutation.
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By further examining the average percent activity of mutants associated with
amino acid positions exhibiting positively or negatively correlated motions in the wildtype enzyme, it remains apparent that there is no statistically significant relationship
between the degree of correlated motion and the impact of the amino acid position on
activity. Figure 4.4 demonstrates that as amino acid positions exhibiting greater negative
correlated motions are considered, the average activity of the corresponding mutants does
not significantly decrease. Similarly, in figure 4.5, as amino acid positions exhibiting
greater positively correlated motions are considered, the average activity of the
corresponding mutants does not significantly decrease. As shown in figure 4.4, these
results indicate that positions exhibiting significant correlated motions are not more
critical for the function of the enzyme.
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Figure 4.4: The average percent activites of the mutants at positions exibiting highly negativly
correlation. (The P-value for the significance of difference between average of any two groups
was >0.05)
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Figure 4.5: The average percent activites of the mutants at positions exibiting highly positive
correlation. (The P-value for the significance of difference between average of any two groups
was >0.05)
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To check if correlation to active site residues has any special importance, we
repeated every part of our analysis considering only those correlated pairs where one of
the pair of residues was within active site region (within 4.5 Å of ligand). As it can be
seen in table 4.2, the positions with high correlated motions are not more critical for the
catalytic activity.
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Table 4.2: Summary of catalytic activities within correlation coefficient groups. (Only
correlation to the active site residues have been taken into consideration)
Correlation
coefficient(Cij)

Number of
total
positions in
group

Number
of
position
studied
in
experiment

Number of
positions
with “zero”
activity

Fraction
of
position
that
upon mutation
result in 10%
of wild type
activity
as
observed
in
experiment

Group 1

Cij<-0.28

24

17

12

71

Group 2

-0.12Cij

28

16

10

62.5

The P-value for the significance of difference between fractions of “zero” activity
positions of groups 1 and 2 is 0.14.
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To explore the connection between correlated motions and activity more directly,
we quantified the degree of change in correlated motions upon single amino acid
mutations. This “degree of change” in correlated motion is calculated as a squared
Euclidian distance between the mutant and wild-type distance matrices where each
element of the matrix corresponds to an orthogonal dimension. The degree of the change
in the correlated motion upon mutation was then compared to the corresponding change
in activity, as measured experimentally. The results indicate no significant nonparametric correlation (r=0.192) between the change in correlated motions upon mutation
and the change in activity (figure 4.6).
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Figure 4.6: The correlation between rank of experimental activity and rank of degree of change in
correlated motions upon single amino acid mutations.
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It should be noted that the dynamical anti-correlations observed in the HIV-1
protease Michaelis complex (figure 4.7) were smaller in magnitude than those observed
with other proteins. While relationship between correlated motion and activity in HIV-1
protease remains dubious, this could be the result of relatively weak correlated motions
observed in the HIV-1 protease/MACA Michaelis complex. Other enzyme may exhibit
stronger correlated motions and a clearer relationship between these motions and activity.
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Figure 4.7: Covariance matrix for the motion of Ca atoms in wild type HIV-1 protease bound to
MA/CA substrate.
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CONCLUSIONS

The present study suggests that dynamics, as characterized by the correlated
motion of residues, does not play any significant role in describing the activities of
experimentally studied mutants of HIV-1 protease. And therefore, dynamics does not
appear to be a significant constraint on the evolution of HIV-1 protease. The inferences
of present study are based on the analyses of available experimental information about
HIV-1 protease, and do not necessarily provide evidence in favor or against of the
proposal of dynamic influences on enzyme catalysis in general. However, our analyses
suggest that the evolutionary outcomes of HIV-1 protease are not significantly regulated
by dynamics.
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CHAPTER FIVE

ROLE OF FOLD STABILITY AS A CONSTRAINT ON THE EVOLUTION OF
HIV-1 PROTEASE

ABSTRACT
The deleterious effects of amino acid mutations on the fold stability of an enzyme
can impose a significant constraint on its evolution. In the present study, we have
assessed the role of fold stability on the evolvability (ability of enzyme to acquire
mutations) of HIV-1 protease. We have used the FoldX protein design suite to estimate
the effect of single point mutations on the fold stability of HIV-1 protease. In the first
part of our study, we have examined the role of fold stability change resulting from single
point mutations on the catalytic activity of HIV-1 protease. In the second part of our
study, we have identified different patterns of mutations from analyses of the HIV-1
protease sequence database, and compared these patterns to the change in fold stability
caused by relevant mutations. We have observed a significant tradeoff between
evolvability and fold stability for HIV-1 protease, and therefore, our study suggests that
fold stability imposes a significant constraint on the evolution of HIV-1 protease.
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INTRODUCTION

The epidemic acquired immunodeficiency syndrome (AIDS) is caused by the human
immunodeficiency virus (HIV)[119]. Two species of HIV have been identified (HIV-1
and HIV-2), out of which HIV-1 is the best characterized and studied due to its extensive
prevalence among patients. HIV-1 is a retrovirus and the genetic information for the
reproduction of this virus is encoded in the form of RNA[16]. Once this virus enters into
the living cell, the structural components of virus are produced in subsequent steps with
the assistance of two virally encoded enzymes, viz. HIV-1 reverse transcriptase and HIV1 integrase, along with the help of cellular machinery. At the final step of reproduction,
the Gag and Gag-Pol polyproteins of the new virus are cleaved into functional proteins
with the help of another virally encoded enzyme known as the HIV-1 protease, thus
producing the mature virus[16]. Due to its key role in the viral maturation process, the
HIV-1 protease has been a primary therapeutic target in the treatment of AIDS[96].
However, the replication process of HIV-1 protease is very inefficient and erroneous. The
relatively high replication rate of the virus (108-109 virions/day) complimented by the low
replication fidelity (5x10-4 mutations per nucleotide per generation) results in the rapid
accumulation and selection of different mutational variants of HIV-1 protease[5]. Some
of these variants are drug resistant and are preferably selected in the presence of protease
inhibitors. This process of acquiring mutations within HIV-1 protease can also be seen as
an evolutionary event.
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The deleterious effects of mutations on the functional properties of an enzyme act as a
major constraint on its evolution. The change in fold stability (Gfold) of an enzyme
upon mutation is one such constraint[22]. In a number of previous experimental and
theoretical studies, it has been shown that the majority of single point mutations have a
destabilizing effect on a protein[120-123]. In previous theoretical studies, which were
performed with all possible mutations within different proteins using experimentally
validated FoldX algorithm[124], 70% of mutations were found to have a destabilizing
effect with more than 20% mutations having destabilizing effect of >2 kcal/mol[125]. In
another theoretical study examining 246 new-function (function altering) mutations
observed in directed evolution experiments performed on 22 different enzymes, it was
found that the new-function mutations on average have destabilizing effect (Gfold =
0.9kcal/mol) on enzyme, which was close to average destabilization effect (Gfold = 1.3
kcal/mol) caused by every mutation observed in directed evolution[126].
The fold stability of HIV-1 protease, and its ability to bind substrate and
corresponding transition state can be considered as one of the most important constraints
on its evolution. In order to successfully accommodate an amino acid mutation in the
HIV-1 protease sequence, these constraints should be satisfied so that HIV-1 protease can
remain catalytically active and perform its essential function. The role of substrate and
transition state binding as constraints on the evolution of HIV-1 protease have been
characterized in previous studies, where it has been shown that drug resistant mutations
don’t have a significant effect on the substrate and transition state binding [127-129].
These observations about drug resistance mutations provide evidence of selection for
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mutations that don’t significantly affect substrate or transition state binding. However,
the role of fold stability in the evolution of HIV-1 protease has not been very well
quantified or discussed.
In the present study, we have examined the relationship between Gfold and the
evolvability (ability of enzyme to acquire mutations) of HIV-1 protease. The
experimentally validated FoldX algorithm[124] was used to estimate Gfold. As
discussed previously, the FoldX algorithm has limited accuracy in predicting the stability
change of individual mutations, but performs very well in predicting the average change
in stability for a group of mutations [125, 130]. Therefore, we have looked for the
average stability change of a group of mutations in every part of our study. We have first
estimated Gfold for all possible mutations in HIV-1 protease and examined general
characteristics of the distribution of amino acid mutations over Gfold values. To
examine the role of Gfold in the effect of random mutations on the HIV-1 protease
activity, we have divided the mutants into three groups based on their experimental
activity values and estimated average Gfold for each of these three groups. In order to
get more insight into the effect of Gfold on the evolvability of HIV-1 protease, we have
next determined the amino acid position entropies, mutation frequencies and the
symmetric uncertainty between residue pairs from the analyses of large number
sequences data taken from both drug treated and drug naïve patients. We have used
symmetric uncertainty as the measure of mutational correlation between residue pairs.
The patterns in position entropies, mutation frequencies and symmetric uncertainties
were then rationalized using Gfold information from the relevant mutations. In brief,
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with the help of experimental information, bioinformatics analysis and a computational
fold stability change estimation technique, the present study suggests that the fold
stability imposes a major constraint on the evolution of HIV-1 protease.

101


THEORETICAL BACKGROUND

The general equation describing the enzymatic reaction can be written as


(5.1)
The k1 and k-1 are rate constants for substrate binding and unbinding process, and kcat is
the rate constant for the catalysis step.
For enzyme catalyzed reactions, the Michaelis-Menten formulation provides a
generally accepted quantitative description of enzyme catalysis. According to the
Michaelis-Menten formulation[131, 132], the rate of the reaction () can be written as:

v=

k cat [ E ] 0 [ S ] 0
 
K M + [ S ]0







(5.1)

Where, [E]0 and [S]0 represent the initial concentrations of enzymes and substrate, and
K M = ( k cat + k −1 ) / k1

In the case of HIV-1 protease, two monomeric units (M) join to form the active
enzyme[133], which can be represented as:
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The kd1 and kd-1 represent the rate constant for the dimerization process. The rate of the
HIV-1 protease catalyzed reaction can now be written as:

v=

k cat k1d [ M ] 02 [ S ] 0
k −d1 ( K M + [ S ] 0 )

(5.2)

If it is assumed that mutations within the enzyme only affect the fold stability and
every other parameter describing the reaction rate are insensitive to mutations, then
mutations will affect the reaction rate through the initial concentration of enzyme ([E]0 or
[M]0). Assuming enzyme folding process (step 1 in equation 5.1) establishes a prior
equilibrium, the relationship between concentrations of folded and unfolded enzyme can
be written as Kfold =

[E]/[U] , where [E] and [U] are the concentrations of folded and

unfolded enzyme and K is the equilibrium constant of the reaction which is related to the
folding free energy (Gfold) by Gfold=-RTlnKfold. A mutation which changes the fold
stability by Gfold, will result into new folded ([E’]) and unfolded ([U’]) concentrations
of enzyme, which are related by the new equilibrium constant K’fold (Gfold+Gfold=RTlnK’fold). Since the total concentration of enzyme remain unchanged ([E]+[U] =
[E’]+[U’]), we can derive a relationship between concentration of folded conformations
at two different free energy values, which is
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[E' ] =

K ' (1 + K )
[E]
K (1 + K ' )

The extent of the effect on the reaction rate will depend on the impact of the
mutation on fold stability and the intrinsic fold stability of the enzyme. In previous
studies, it has been shown that most random mutations have destabilizing effect on
protein. As shown in figure 5.1(a), the catalytic activities of comparatively stable
enzymes are less sensitive to the stability changes caused by amino acid mutations, and
the enzymes which are comparatively less stable are very sensitive to the stability change.
In the case of HIV-1 protease type of systems, where two monomeric units join together
to form the active enzyme, the reaction rate is even more sensitive to the change in
stability compared to the monomeric proteins (figure 5.1(b)).
The fold stability of monomeric HIV-1 protease has been estimated to be ~1.05
kcal/mol[23]. The stability of HIV-1 protease is very marginal compared to most of the
known proteins which are found to be stable by 5-15 kcal/mol[134]. As shown in the
figure 5.1(b), the catalytic activity of HIV-1 protease will be extremely sensitive to the
change in fold stability caused by the mutations and therefore, fold stability can act as the
major constraint in the evolution of HIV-1 protease.

104


Figure 5.1: Graphs showing relationship between fold stability of enzyme (Gfold), its % activity and change in fold stability (Gfold) for
(a) monomeric enzymes (b) HIV-1 protease type enzymes which are active as a dimer. [For figure 1(a) %Activity = f *100, and for figure
1(b) %Activity=f2*100. Where f = e

− ( ΔG fold + ΔΔG fold ) / RT

(1 + e

− ΔG fold

)/e

− ΔG fold / RT
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(1 + e

− ( ΔG fold + ΔΔG fold ) / RT

).

RESULTS

1. The Gfold distribution of HIV-1 protease:

The general characteristics of the effect of all possible single amino acid mutations
and single nucleotide mutations on the fold stability were observed by analyzing the

Gfold values upon these mutations. The characteristic shape of the distribution curve of
all possible single amino acid mutations over Gfold values (figure 5.2a) is similar to
what has been observed with other proteins[125]. However, the distribution is shifted
indicating a greater degree of destabilization compared to other proteins. A total of ~18%
single amino acid mutations were predicted as stabilizing for HIV-1 protease, compared
to ~30% for the proteins examined in previous studies[125]. This suggests that the HIV-1
protease has more tendencies to be destabilized upon amino acid mutations compared to
other proteins.

About 50% of single amino acid mutations were found to have

destabilizing effect of more than 1 kcal/mol (the fold stability of HIV-1 protease is ~1.05
kcal/mol). The distribution curve of all possible single nucleotide mutations over Gfold
is remain very similar to distribution curve of single amino acid mutations, with ~17%
mutations were predicted to be stabilizing (figure 5.2b).
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Figure 5.2: The distribution curve of Gfold values of (a) all possible 19 mutations at each amino
acid positions, (b) all possible single nucleotide mutations in gene encoding HIV-1 protease. The
data are presented in histogram format, with bin width of 1 kcal/mol.
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2. Role of Gfold on the catalytic activity of random mutations:

The role of Gfold on the catalytic activity of HIV-1 protease was examined by
exploring

its

relationship

with

activities

of

experimentally

studied

random

mutations[135]. For these mutations, we have compared the activities values determined
experimentally with predicted effects on protein stability. The mutations were divided
into three groups based on their experimental activities. The group I represent mutants
with 0% activity, group II represents mutants with 0 to ~10% activity and group III
represents mutants with >10% activity. The average Gfold for all three groups of
mutants were then estimated using FoldX. As shown in the table 5.1, the average Gfold
for the group III mutations (0.62 kcal/mol) is significantly lower compared to the average

Gfold value (1.71 kcal/mol) for Group I mutations and average Gfold value (1.55
kcal/mol) for Group II mutations. This suggests that the loss in activity for group I and
group II mutations is significantly driven by the loss in fold stability. Further, FoldX has
predicted 20% mutations as stabilizing within group III, compared to 2% in group I and
5% in group II, which further implies that the distribution for group I mutations over

Gfold is significantly different compared to the group II and group III mutations.
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Table 5.1: Summary of average Gfold values for different activity groups of mutations.
% Activity

Number of

Average %

Average

% of

(A)

mutations

activity of

Gfold

stabilizing

mutations

(kcal/mol)

mutations

Group I

A=0

50

0

1.71(0.19)

2

Group II

0 <A  ~10

20

~3.3

1.53(0.23)

5

Group III

A > 10

35

~69.1

0.63(0.15)

20

-The standard errors of mean associated with averages are given in parenthesis next to the
value.
-The P value for the significance of the difference between means of group I and group
III is 0.000062 (d.f.=83), and between means of group II and group III is 0.00145
(d.f.=53). [d.f. =degrees of freedom]
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3. Correlating Gfold with position entropy:

The role of stability in describing the position variability (entropy) in the HIV-1
protease sequence was examined by estimating the effect of mutations on fold stability
and comparing this to experimentally determined sequence entropies. We first
determined the amino acid position entropies for HIV-1 protease sequence by analyzing
the protease sequences obtained from both, drug treated and drug naive patients[55]. We
excluded the positions 1 to 4 and 96 to 99 from our analysis as terminals of HIV-1 act as
the substrate for itself[133], and therefore conservation of these positions are less likely
to be driven by stability. The amino acid positions within HIV-1 protease were first
grouped based on entropy values (group I with entropy value <0.1, and group II with
entropy value 0.1). We have then identified the mutations with the least destabilizing
effect from the data of Gfold for all 19 mutations of each amino acid position within
HIV-1 protease using FoldX. The average change in Gfold for these least destabilizing
mutations within each position entropy group was then estimated (table 5.2).
As reported in the table 5.2, the positions with high sequence entropy are more likely
to mutate without significantly undermining the ability of protease to fold to its
catalytically relevant structure, compared to the group of positions with comparatively
low entropies. In these conserved positions, a mutation is more likely to destabilize the
protease to an extent where it will significantly lose its activity. This suggests that

Gfold has a key role to play in the evolvability of HIV-1 protease.
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Table 5.2: Summary of Gfold within entropy groups.
Entropy Number
Range

Average change in Average change in Average change in % of position

of amino Gfold for
acid

least Gfold for two least Gfold for three with at least

destabilizing

positions mutations

destabilizing

least destabilizing one

mutations (kcal/mol)

mutations

stabilizing

(kcal/mol)

mutation

(kcal/mol)
Group I

<0.1

30

0.63(0.33)

0.82(0.26)

0.96(0.22)

33.3

Group II

0.1

56

-0.13(0.12)

0.04(0.09)

0.19(0.08)

55.36

-The standard errors of mean associated with averages are given in parenthesis next to the value.
- The P value for the significance of the difference between means of group I and group II (a) for least destabilizing
mutations is 0.0108(d.f.= 84), (b) for two least destabilizing mutations is 0.00073(d.f.= 170), and (c) for three least
destabilizing mutations is 0.000093 (d.f.= 256).
- Five positions in group I were found to have Gfold values for least destabilizing mutations >10kcal/mol, and were
excluded from the analysis (see the method section)
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4. Effect of Gfold on the frequency of mutations:

We further examined the role of Gfold on the evolvability of HIV-1 protease by
exploring the relationship between the frequency of a mutation and its effect on the fold
stability of HIV-1 protease. The frequency of every mutation in HIV-1 protease was
evaluated using the HIV-1 protease sequence database from treated and untreated
patients[55]. The positions from 1 to 4 and from 96 to 99 in HIV-1 protease were
excluded from our analysis as these amino acids act as the substrate for itself, and
therefore the fold stability is not the prime factor for their conservation. We divided all
mutations observed in the database based on their frequencies of appearance (group I
with frequency >0.008, group II with frequency 0.008 but >0, and group III of the
mutants which were not observed in sequence analysis). The average Gfold for the
mutations within each group was estimated using FoldX. As shown in table 5.3, the high
frequency mutations were found to be less destabilizing on average compared to the low
frequency mutations. The average destabilizing effect of zero frequency mutations were
observed to be highest. This analysis further suggests that the fold stability plays a key
role in evolvability of HIV-1 protease.
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Table 5.3: Summary of Gfold within frequency groups.
Frequency (f)

Number of

Average

% of

range of

mutations

Gfold

stabilizing

(kcal/mol)

mutations

mutations
Group I

f >0.008

104

0.64(0.11)

25

Group II

0.008  f >0

533

1.31(0.07)

18.01

Group III

f=0

1037

1.95(0.06)

13.89

-The standard errors of mean associated with averages are given in parenthesis next to the
value.
- The P value for the significance of the difference between means of group I and group
II is 0.000074(d.f.= 635), between I and III is <0.000001(d.f.= 1139), and between II and
III is <0.000001(d.f.= 1568).
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5. Correlated mutations and stability effect.

A high degree of cooperativity has been proposed among mutations in HIV-1
protease, which is reflected as the covariance of these pairs in sequence database[136,
137]. In several previous studies regarding mutational pairs, it has been proposed that one
of the mutations in a pair compensates for the destabilizing effect of the other
mutation[126, 138, 139]. In order to study the role of stability on the covariance of the
mutations in HIV-1 protease, we have first identified the pairs with high symmetric
uncertainty value (>0.05) from the sequence database of treated and untreated patients.
Currently, no computational algorithm has been extensively validated for predicting the
effect of double mutations on fold stability. Therefore, our ability to fully address the role
of fold stability on the observed covariance of mutational pairs in sequence database is
limited. To examine the role of fold stability on the covariance of mutational pairs by
estimating Gfold upon single point mutations, we ranked the mutations within each pair
based on its conditional probability, and formed groups of higher conditional probability
(group I) and lower conditional probability (group II) of mutations from each pair. As
demonstrated in a previous study, mutations with higher conditional probability are more
likely to appear first during evolution, compared to the second mutation in a pair[139].
As shown in the table 5.4, the group I mutations (with high conditional probability)
are less destabilizing (~16% mutations being stabilizing) compared to the group II
mutations (mutations with low conditional probability). The group I mutations, however,
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do not demonstrate a complete compensation of the destabilizing effect caused by the
group II mutations. Since we have studied only single point mutations, and a strong
epitasis has been observed among the mutations of HIV-1 protease[140], our ability to
address the effect of stability on the covariance of mutations is limited. However, these
results indicate that mutations appearing first could compensate for the destabilizing
effect of the second mutation in a pair, and therefore, one of the pair mutations can play a
role in maintaining catalytically relevant fold of HIV-1 protease.
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Table 5.4: Summary of Gfold within conditional probability groups.
Number of

Average

% of

mutations

Gfold

stabilizing

(kcal/mol)

mutations

Group I

137

0.72(0.08)

16.06

Group II

137

1.69(0.13)

8.76

-The standard errors of mean associated with averages are given in parenthesis next to the
value.
- The P value for the significance of the difference between means of group I and group
II is <0.000001 (d.f.= 272)
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DISCUSSION

In order to fully explore the role of fold stability as a constraint on evolution of HIV-1
protease, we have extended our study beyond naturally selected mutations (drug resistant
mutations and mutations observed during directed evolution). Naturally selected
mutations appear after satisfying the constraints on evolution, and therefore, any study
performed with these mutations to identify and characterize the constraints on evolution
is likely to have limited success. In every part of the present study, we have compared the
effect on fold stability caused by evolutionarily more favored mutations (high activity
mutations, high entropy positions, high frequency mutations and high conditional
probability mutations) to the effect on fold stability caused by evolutionary less favored
mutations (low activity mutations, low entropy positions, low frequency mutations and
low conditional probability mutations). In each case the evolutionary more favored
mutations were observed to have less destabilizing effect compared to the evolutionary
less favored mutations. Results of this study suggest that the Gfold plays a key role in
describing the relative activities of the HIV-1 protease mutations, and therefore fold
stability imposes a significant constraint on the evolution of HIV-1 protease.
As mentioned previously (figure 5.1), the sensitivity of the catalytic activity of an
enzyme toward Gfold depends on its fold stability. Consistent with this fact, a previous
study performed with relatively stable proteins has observed no distinct tradeoff between
new function and stability[126]. However, in the case HIV-1 protease which is stable by
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only ~1.05kcal/mol[23], we have observed a significant tradeoff between stability and
evolvability. This also suggests that every time a drug resistant mutation appears, the
stability constraint has to be satisfied, along with reducing the affinity for inhibitor and
maintaining the affinity for substrate and transition state. And therefore, in future attempt
to predict the drug resistant mutations, stability should also be taken into consideration.
We have used FoldX to estimate the average Gfold for groups of mutations in every
part of our study. In several previous studies, it has been shown that computational
algorithms (including FoldX) have limited accuracy in predicting the Gfold for
individual mutations[130]. However, they perform very well in estimating the average

Gfold for several mutations [124, 125, 130]. The ability of FoldX to accurately predict
the average Gfold for large set of mutations has been successfully utilized in several
previous studies [125, 126]. More discussion about FoldX and its predictive ability can
be found elsewhere[124].
As our results suggest that fold stability imposes a major constraint on the evolution
of HIV-1 protease, accurate knowledge of the change in fold stability upon amino acid
point mutation(s) appear to be key information in predicting evolutionary outcomes (such
as drug resistant mutations) of HIV-1 protease. Therefore, our study not only indicates
that fold stability act as a major evolutionary constraint, but also emphasizes the potential
value in improving fold stability prediction algorithms.
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METHODS

The methodological details of present work can be classified in to two parts. In one
part, we performed sequence analyses on HIV-1 protease to calculate symmetric
uncertainties between pairs of sequence positions, position entropies of sequence
positions and frequencies of specific mutations. In the other part of our study, we
estimated changes in fold stability (Gfold) upon single point amino acid mutations.

1. HIV-1 protease amino-acid sequence analyses

All nucleic acid sequences corresponding to the HIV-1 subtype B protease obtained
from both treated and untreated patients were downloaded from Stanford HIV RT and
Protease Resistance Database[55] on February 25, 2010. In case of multiple sequence
entries from the same patient, only the most recent data entry for that patient is included
in the analysis.
(a). Position entropy:
The entropy (H) of a position x was calculated as
 H ( x ) = −  P ( x i ) log 2 P ( x i )
allx i
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Where, xi is the mutational variant at position x.
(b). Symmetric Uncertainty:
Symmetric uncertainty is a normalized version of the mutual information and
varies between 0 and 1. The symmetric uncertainty [U(x,y)] between two random
variables (positions) x and y can be expressed as

U ( x, y ) = 2

I ( x; y )
H ( x) + H ( y )

The I(x,y) in the above equation is the mutual information between random variables x
and y, and can be expressed as
I ( x; y ) = H ( x ) + H ( y ) − H ( x , y )

Where,

H ( x, y ) = −   P ( x i , y i ) log 2 P ( x i , y i ) is the joint entropy between positions
allx i ally i

x and y.

2. Estimation of fold stability change upon mutations.

The changes in fold stability (Gfold) of HIV-1 protease upon single point amino
acid mutations were estimated using the protein design tool FoldX (version 3.0)[141]. We
followed exactly the same procedure to estimate Gfold as has been used in previous
studies [125, 126]. We have chosen a high resolution crystal structure of the monomeric
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HIV-1 protease for our study (PDB ID: 2PC0[142]). We first optimized the crystal
structure using the repair function of FoldX. The crystal structure had a Q7K mutation,
which was back mutated to the wild type sequence using FoldX. In the next step,
structures corresponding to all possible single point mutations were generated, and
corresponding energies were estimated using the position scan function of FoldX. The

Gfold values corresponding to each mutation were estimated by comparing the energies
of mutant structures with energies of corresponding wild type structures. We have used a
conversion formula [Gfoldexperimental = (GfoldFoldX + 0.078)/1.14] to adjust the FoldX
energies as suggested in previous studies[125, 126]. Any mutations showing an
unphysically high Gfold (>10 kcal/mol) were excluded from our analysis. There were
55 such mutations (2.9% of all possible mutations), which were excluded from out study.
P-values used to determine the significance of the difference between average Gfold
values were determined using the two-tailed test based on the t-distribution[143].
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CHAPTER SIX

THE EVOLUTION OF CEFOTAXIMASE ACTIVITY IN THE
TEM -LACTAMASE

ABSTRACT
The development of a molecular level understanding of drug resistance through lactamase is not only critical in designing a newer generation antibacterial agents, but
also in providing insight into evolutionary mechanisms of enzymes in general. In the
present study, we have evaluated the effect of four drug resistant mutations (A42G,
E104K, G238S, and M182T) on the cefotaximase activity of the TEM-1 -lactamase.
With the help of computational methods, we have been able to correctly identify the
relative order of activities for these four single point mutants compared to wild type. In
our further analyses of structural properties, we have observed that the changes in
catalytic efficiency for mutant enzymes are correlated to structural changes within the
binding site. Based on the energetic and structural analyses of the wild type and mutant
enzymes, structural rearrangement is suggested as a mechanism of evolution of drug
resistance through TEM -lactamase. The present study not only provides a molecular
level insight into the effect of four drug resistant mutations on the structure and function
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of the TEM -lactamase, but also sets up the direction for future molecular level analysis
of complete evolutionary trajectory for this class of enzymes.
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INTRODUCTION

-lactam antibiotics are the antibacterial agents that inhibit bacterial growth by
inhibiting cell wall synthesis[6]. The first drug in this class was Penicillin G
(benzylpenicillin), which was introduced into clinical practice during 1940s[25].
However, soon after Penicillin G was brought into regular practice to treat bacterial
infections, bacteria was found to develop resistance against this drug by secreting an
enzyme called -lactamase[6, 25, 26]. -lactamase is believed to evolved from Penicillinbinding-proteins (PBPs)[144-147], which are the natural targets of the -lactam
antibiotics. There is another view about the evolution of serine -lactamase which
suggests that these are ancient enzymes, and originated over two billion years ago[148].
The -lactamase catalytically hydrolyzes the -lactam ring and therefore inactivates this
class of antibiotics. Based on the sequence similarity, -lactamase has been subdivided
into four classes[144, 149, 150]. Class A, C and D are the active site serine enzymes, and
class B requires metal for its catalytic activity. The class A TEM -lactamase is one of
the most commonly found plasmid-mediated -lactamase within Gram-negative
bacteria[151], and our further discussion will be focused on TEM -lactamase.
The TEM -lactamase uses the hydroxyl group of its active site serine residue
(Ser70) as the key functional group for catalyzing the hydrolysis reaction[152]. Once the

-lactam antibiotic is accommodated into the binding pocket of this enzyme, acylation,
deacylation and product release are the three steps through which hydrolysis takes
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place[153]. Several different mechanisms for this reaction have been proposed.
According to one of the latest proposed mechanisms for the hydrolysis of
benzylpenicillin[152], the key acylation reaction believe to take place in two steps. In the
first step, indirect activation of nucleophile Ser70 takes place by Glu166. The Glu166
abstracts a proton from a bridging water molecule, and the resultant hydroxyl causes
deprotonation of Ser70. This deprotonated Ser70 attacks the carbonyl group of the lactam ring, thus forming a tetrahedral intermediate[152]. In the second step of acylation
where the acyl-enzyme complex is formed from the tetrahedral intermediate, the leaving
thiazolidine nitrogen is protonated by Ser130, which is reprotonated by Glu166 via
Lys73[152]. These reactions result in the complete breakdown of the lactam bond. In a
kinetic study of the hydrolysis reaction of the -lactamase against benzylpenicillin, the
rate constants for every step of the hydrolysis reaction were experimentally
determined[154]. It was found that no single rate-determining step exists for -lactamase
catalyzed hydrolysis raction of benzylpenicillin[154]. The rate constants for all three
steps of hydrolysis (acylation, deacylation and product release) were determined to be
approximately the same, and the overall hydrolysis reaction was found to be diffusion
controlled.

It is therefore concluded that -lactamase functions as a fully efficient

enzyme[144, 154].
In order to evade the catalytic action of the -lactamase, several new classes of lactam antibiotics were designed with the aim of synthesizing an antibiotic that cannot be
hydrolyzed. Cefotaxime is one of these later generation drugs (third generation
cephalosporin -lactam antibiotic) that cannot be efficiently hydrolyzed by the TEM-1 -
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lactamase[151]. One of the strategies in designing these newer generation drugs was to
make their side groups around the -lactam ring bulkier so that they cannot fit into the
binding pocket of -lactamase without compromising its ability to bind the PBPs. It is
believed that the bulkier groups around the -lactam ring in cefotaxime compared to the
benzylpenicillin (figure 6.1) prevent its binding to the -lactamase, and therefore prevent
its hydrolysis. However, later it was found that five point mutations within TEM-1 lactamase gene produce a variant of -lactamase which is capable of hydrolyzing the
cefotaxime and therefore causes drug resistance[27, 28]. This consists four missense
mutations[155] [A42G, E104K, M182T, and G238S] and one 5’ non-coding
mutation[156] [g4205a]. Since the reactive part [-lactam ring] of cefotaxime is identical
to that of the benzylpenicillin (figure 6.1), and the hydrolysis reaction catalyzed by lactamase is diffusion controlled, the cefotaxime binding process can be considered as the
rate limiting step in the cefotaximase activity of -lactamase. And therefore, it can be
thought that during the evolution of improved activity against cefotaxime, -lactamase
increases its affinity for the cefotaxime. Since the core structure of the -lactam ring
remains unchanged in cefotaxime from benzylpenicillin, the activation energies for the
reaction can be thought to be approximately same as in the case of benzylpenicillin. This
hypothesis of substrate binding being rate limiting step in the case of the -lactamase
catalyzed reaction has already been experimentally verified with cephaloridine[157]
(another 3rd generation cephalosporin -lactam antibiotic). In the experimental study, the
reaction of mutant -lactamase was studied against benzylpenicillin and cephaloridine,
and it was found that the acyl-enzyme structures do not account for the faster hydrolysis
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of the benzyl penicillin[157]. It was suggested that the relative activity towards
benzylpenicillin and cephaloridine for class A -lactamase must be determined prior to
acyl-enzyme formation[157], which is the substrate binding step.
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Benzylpencillin

Cefotaxime

Figure 6.1: The chemical structures of benzylpenicillin and cefotaxime.
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Development of drug resistance by increasing the catalytic activity of -lactamase
against cefotaxime can also be seen as the evolutionary event within a background of an
external pressure (i.e. the presence of a drug)[25, 158]. And therefore, this process of
developing drug resistance in bacteria can be utilized to address evolution related
questions. Considering these facts, the effect of the genetic background on the phenotypic
consequence of a mutation (also termed as the “Epistasis”) has been experimentally
addressed using TEM -lactamase and cefotaxime as a system[29]. There are 5! = 120
possible mutational trajectories (considering all five point mutations in the gene, and
assuming only single mutations take place at each step) through which the suboptimal
allele (wild type -lactamase) can evolve to an optimal allele (five point mutated lactamase). In the case of “Sign Epistasis”, all mutational trajectories would not be
assessable with equal probability[8]. In the experimental study, all possible mutational
trajectories from the suboptimal to optimal allele were constructed and their probability
of realization was assessed[29]. It was found that 102 of the 120 mutational paths were
selectively inaccessible, and only 18 paths were found to increase in resistance and
fitness at each step and therefore accessable to Darwinian selection[29]. This experiment
has provided concrete evidence of “Sign Epistasis” and demonstrated constraints in
evolution[159].
From the above discussion, it is clear that the development of a molecular level
understanding of -lactamase evolution has a great deal of implications in the
development of better antibiotics, along with providing more general insight into enzyme
evolutionary mechanisms. In the present study, we have studied the effect of first line of
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mutations in evolutionary trajectory [A42G, E104K, M182T, and G238S] as studied in
the previous experiment, on the cefotaximase activity of TEM-1 -lactamase. The noncoding mutation (g4205a) is not included in our present study as this does not directly
affect the chemical structure of the -lactamase. As discussed earlier, the substrate
binding process is most likely the rate limiting step, and therefore we have estimated the
change in binding affinity for cefotaxime upon these four single mutants relative to the
wild type affinity and compared this to the experimental activity. We have observed
excellent agreement between change in binding affinities of mutant enzymes and its
experimentally reported minimum inhibitory concentrations[29] (MICs). The MIC and
catalytic activity has been shown to be almost linearly correlated for bacterial
resistance[160]. We have further analyzed the structural changes upon mutations and
observed that the substantial increase in catalytic activity for the G238S and E104K
mutant enzymes is correlated with significant restructuring at active site, which is
consistent with the previous experimental evidence regarding the G238S mutation[161163]. The present study provides a molecular level insight into the effect of the four drug
resistance mutations on the cefotaximase activity of -lactamase, which is not only
helpful in designing new class of antibiotics but also provides molecular level insight into
the first step of the evolutionary trajectory through which bacteria become drug resistant.
The findings of present work also provide a firm basis for the future molecular level
study of the complete mutational trajectory for the evolution of TEM -lactamase and
other enzymes of this class.
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METHODS

To assess the effect of four mutations (G238S, E104K, A42G and M182T) on the
binding affinity of TEM -lactamase for cefotaxime, we simulated modeled mutant
enzymes as well as the wild type enzyme bound to cefotaxime. As there is no crystal
structure at present for cefotaxime bound TEM -lactamase, cefotaxime was first docked
into the binding pocket of the wild type enzyme structure. In the next step of our study,
mutant enzymes bound to cefotaxime were generated by modeling the mutations in the
wild type structure. Molecular dynamics simulations and MM-PBSA free energy
calculations were performed in subsequent steps. The details of the methodology used in
the present study are given below.

1. Docking of Cefotaxime into binding pocket:

Cefotaxime was docked into the crystal structure of TEM-1 (wild type) -lactamase
(PDB ID: 1BTL[164]) using Autodock4[165]. The amino acid sequence of this crystal
structure is consistent with the definition of wild type enzyme used in the experimental
study[29]. This structure has also been used in several previous theoretical studies with
benzylpenicillin and cephalosporin[166, 167]. Also, Autodock has been successfully used
to determine the enzyme bound structures of benzyl penicillin and cephalosporin, which
are in close structural resemblance with cefotaxime[166, 167]. The C2-down conformer
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of dihydrothiazine ring of cefotaxime was used for docking as this conformer has been
suggested to be more stable and abundant in the structurally similar molecule
cephalosporin in the enzyme bound state[167]. This conformation was held fixed during
the docking.
Prior to the docking calculations, the active site region was defined as in previous
studies[166, 167]. In order to cover the entire region of the binding site, a sufficiently
large grid around the catalytic site of the enzyme was used within Autodock4. The
conformational searches were performed using a genetic algorithm (GA), and a
maximum number of energy evaluations per GA run were set to 25000000. The rest of
the parameters were set to the default values within Autodock4.

2. Ligand parameterization.

The parameterization of cefotaxime was performed on its docked conformation
(without the receptor). The cefotaxime was assigned force field parameters from the
general

AMBER

force

field[168]

(GAFF)

for

small

molecules,

using

the

ANTECHAMBER package[169]. The partial atomic charges on the cefotaxime were
derived using R.E.D tools[170]. The cefotaxime was first minimized in Gaussian03[171]
using HF/6-31G* basic sets. In next step, the partial atomic charges were derived using a
two stage restricted electrostatic potential[172] (RESP) fitting protocol within the R.E.D
tools.
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3. Modeling the mutations:

The mutations in TEM-1 -lactamase enzyme were made using the tools of
MODELLER, as developed by Feyfant et. al[173]. This method uses a combination of a
knowledge based potential and a simulated annealing protocol to build side chain
conformations of mutant residues. The details of this protocol can be found in the original
publication[173]. Since none of the mutant positions were found to make any significant
contact with cefotaxime in the wild-type modeled complex, the presence of the ligand in
the binding pocket was not a requirement for the accurate modeling of side chain
conformations of mutant amino acids. Therefore, the mutations were built within the
original crystal structure of TEM-1 -lactamase (PDB ID: 1BTL).

4. System Preparation and Molecular Dynamics simulation protocol:

In order to accurately model the Michaelis complex, a water molecule was placed
between residues Ser70 and Glu166 of enzymes taking structural information from
previous studies[152, 167]. This water molecule has a key role to play during
catalysis[152], however, this water has not been shown to make any significant
contribution towards the ligand specificity[166, 167]. All enzyme ligand complexes were
solvated in an octahedral simulation box of TIP3P water molecules, using tleap within
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Amber10[174, 175]. The Amber ff99SB[176] force field was used to describe the protein
part of the enzyme-cefotaxime complex. The minimum distance between any of the
atoms of the solvated complex and the box boundary was maintained to at least 10 Å.
The systems (all enzyme-ligand complexes as well as unbound enzymes) were
neutralized by the addition of potassium ions.
During all energy minimization and molecular dynamics simulations, the electrostatic
interactions between atoms were treated using a particle mesh Ewald (PME)
method[177], with a B-spline order of 4 and direct space cutoff of 10 Å. The LennardJones interactions were computed within a cutoff of 10 Å. All the bonds involving the
hydrogen were constrained using SHAKE[178] in Amber10.
In the next step, minimization of the systems was carried out using SANDER module
of the Amber10 package. In the first part of minimization, the solute atoms were held
harmonically restrained (with a very high force constant of 500 kcal/mol/Å2) and the
systems were minimized for 1000 steps using a steepest descent algorithm and 1000 steps
using a conjugate gradient algorithm. In the next part of minimization, the force constant
for the positional restraint on the solute atoms was reduced to 50 kcal/mol/Å2 and the
systems were further minimized for 1000 steps using the steepest descent algorithm.
Once the systems were relaxed, the gradual heating of the systems was performed
within the SANDER module. The systems were gradually heated from 0 K to 300 K
during 100 ps of simulation, with a 1 fs time step for integration. The solute atoms were
restrained with a force constant of 5 kcal/mol/Å2, in order to avoid any significant
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structural deformation during the heating process. After heating, the density equilibration
simulation was performed. The molecular dynamics simulation of the systems were
performed in constant pressure and temperature (NPT) ensemble for 500 ps, with
pressure relaxation time of 1.0 ps and 2 fs time step for integration. The solute atoms
were restrained with a relatively weak force constant of 2 kcal/mol/Å2 during NPT
simulation. The temperature was maintained to an average value of 300K using Langevin
dynamics, with collision frequency of 2 ps-1. After achieving a density equilibration
corresponding to 1atm pressure, all the restraints on the systems were removed and
further simulations were performed in constant volume ensemble (NVT) within the
PMEMD module of Amber10, with a 2 fs time step of integration. Total 30 ns of
equilibration and 10 ns of the production simulations were performed for the free-energy
estimation and structural analysis.

5. MM-GBSA binding affinity calculation:

The binding affinities of cefotaxime to the wild type as well as mutant enzymes were
estimated using an MM-GBSA protocol[179-181]. The MM-GBSA protocol is not only
computationally efficient in comparison to the traditionally used MM-PBSA and other
free energy estimation techniques, but also has been shown to be in excellent qualitative
agreement with MM-PBSA and experiment[37].
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According to the MM-GBSA protocol, the free energy of binding can be estimated
using the following formulation.

GMM-GBSA = GMM + Gsol –TS

Gbind = GMM-GBSAcomplex + GMM-GBSAreceptor - GMM-GBSAligand

Gbind = GMM + Gsol - TS

Where, the Gbind is the binding free energy, GMM is the molecular mechanics free
energy contribution to the binding free energy (which is contribution from the gas phase
energies of isolated molecules), Gsol is the solvation contribution to the binding free
energy and -TS is the contribution from the conformational entropy change. In previous
studies, it has been suggested that the conformational entropy change upon single point
mutation is negligible and can safely be ignored[182, 183]. And therefore, the
conformational entropy change upon mutation has not been included in the present study.
The -loop (residues 161-179) of ligand free

-lactamase has long time scale

motion[184], which cannot be properly sampled on nanosecond time scale simulation.
And therefore, in order to avoid the error caused by the insufficient sampling of the -
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loop, the MM-GBSA energies of complex and receptor was estimated from same
trajectory (see the discussion section for more details). In order to account for the internal
energy change of cefotaxime upon binding, a trajectory from separate simulation was
used for the ligand MM-GBSA free energy calculation.
The molecular mechanics contribution to the binding affinity (GMM) can be written
as the contribution from Columbic (Gelec) interactions, van der Waals (GvdW)
interactions and from internal energy change (Ginte). The internal energy term here
include bond, angle and dihedral energies of a molecule.

GMM = Gelec + GvdW + Ginte

The Columbic, van der Waals and internal energy contributions to the binding affinity
were estimated using exactly the same parameters that have been used for energy
minimization and molecular dynamics simulations. While calculating the interaction
energies, no cutoff was used for non-bonded interactions.
The solvation free energy contribution to the binding affinity can be written as sum of
polar (Gsolpol) and non-polar (Gsolnon-pol) contributions.

Gsolv = Gsolpol + Gsolnon-pol
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The polar contribution to the solvation free energy was estimated using generalized Born
(GB) method in Amber10. The non-polar contribution to the solvation free energy was
calculated using solvent accessible surface area (SASA) method as

Gsolnonpol =  * SASA

The value of 0.0072 kcal/mol/Å2 was used for surface tension coefficient . The SASA
was determined with the MOLSURF method, as implemented in Amber10.

6. Per-Residue decomposition:

The free energy estimated using an MM-GBSA method can be efficiently
decomposed into its per-residue contributors, which can provide further insight into a
binding mechanism. The per-residue decomposition of the MM-GBSA binding affinity
has been successfully used in addressing several questions, including the prediction of
some drug resistant mutations in HIV-1 protease[128].
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The details of the per-residue decomposition of MM-GBSA binding free energy in
AMBER can be found elsewhere[185]. In brief, the contribution of jth residue to the
binding free energy from ith snapshot of species x can be written as:

x
x
G x (i, j ) = G gas
(i, j ) + G solvation
(i, j ) − TS x (i, j )

The contribution of residue j electrostatic (Columbic + polar solvation) free energy can
be obtained by:

x
(i, j ) = −
Gelec

 exp(− k )  q k q l
q q
1
1
1 −
 GB
+  k l

2 i∈ j k 
ε w  f kl (rkl ) 2 i∈ j k ≠l rkl

Where, the first term designate the electrostatic contribution to the solvation free
energy calculated using GB. The second term stands for the Columbic interaction energy.
The w is the dielectric constant, qk and ql are the partial charges on the atoms k and l, and
rkl is the distance between respective atoms. The internal energies (bond, angle, and
dihedral energies) were decomposed based on atom contribution of the residues.
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RESULTS


1. Docked conformation of cefotaxime:

Cefotaxime was docked into the binding pocket of the wild-type -lactamase. The
structure with the highest population, which also has one of the lowest energies, was
selected as the representative of the -lactamase bound structure of cefotaxime (figure
6.2). This low energy solution has the reactive -lactam ring of cefotaxime in the correct
proximity to catalytic residue Ser70. This conformation also makes several contacts (with
residues Ser70, Ser130, Ala237, Arg244, Asn132, Lys234, Ser235), which have been
recognized as the key contact with its structurally similar molecules benzylpenicillin and
cephalosporin in previous studies[166, 167]. A majority of these contacts were found to
be conserved during the molecular dynamics simulation (table 6.1).
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Figure 6.2: Results of the automated docking calculation. In this graph, each bar represents the
docking energy (kcal/mol) and population of a conformational cluster.




141




Table 6.1: The key hydrogen bonds as observed in docking calculations. The distances
between heavy atoms are reported.

Hydrogen bond

Distance (Å)

CEF-O····H-N-ALA237

3.04

CEF-O6····H-N1-ARG244

2.76

CEF-O2····H-N-ASN132

4.80

CEF-O5····H-N-LYS-234

3.25

CEF-O5····H-O-SER-130

2.81

CEF-O5····H-O-SER-235

3.25

CEF-O6····H-O-SER-235

3.03

CEF-O····H-O-SER-70

2.83

CEF-N1-H····O=C-ALA-237

4.00

CEF-N4-H····O=C-PRO-167

3.93
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1. Binding free energy calculations:

The effect of four mutations (A42G, E104K, M182T, and G238S) in TEM-1 lactamase on the binding affinity for cefotaxime was examined. The MM-GBSA binding
affinities were estimated by analyzing 1000 snapshots, taken during the last 10 ns of the
production simulation. The MM-GBSA binding affinities of wild type and four mutants
for cefotaxime are shown in the table 6.2. Out of the four mutants studied, the highest
binding affinity for cefotaxime was observed for the G238S mutation of TEM-1 beta
lactamase. The G238S mutation is also the one that has been shown to exhibit the
maximum MIC (1.410 µg/ml) of cefotaxime[29]. As it has been mentioned earlier, the
MIC and catalytic efficiency for bacterial resistance are lineally correlated[160].
Therefore, the G238S mutation contributes the most towards improving the catalytic
efficiency of the -lactamase by increasing its binding affinity toward cefotaxime. The
E104K mutation ranks second in increasing the binding affinity of the enzyme for
cefotaxime. The MIC of cefotaxime for E104K mutant enzyme was determined to be
0.132 µg/ml[29], which also ranks second after the G238S mutant enzyme. The M182T
mutation which has been found to decrease the MIC compared to the TEM-1 lactamase, was estimated to lower the binding affinity of the enzyme toward cefotaxime.
The binding affinity of the A42G mutant enzyme, which has an MIC equal to wild type,
was found to be very close to that of the wild type structure. Hence, the binding free
energy data shown in table 6.2 suggest that cefotaximase activity of TEM-1 beta
lactamase evolves by increasing its binding affinity (and therefore specificity) for
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cefotaxime, which is consistent with previous experimental studies and proposals[161163].
More insight into the binding mechanism can be obtained by looking into the
different components of the MM-GBSA binding affinity. As shown in table 6.2, the
substantial favorable change for cefotaxime binding affinity in the case of the G238S
mutant enzyme compared to the wild type enzyme is primarily driven by the van der
Waals energy term. This indicates the better accommodation of cefotaxime into the
binding pocket of the -lactamase upon G238S mutation. The E10K mutant enzyme also
increases its binding affinity for cefotaxime compared to the wild type through the van
der Waals component, and appears to follow a mechanism similar to the G238S mutant
enzyme for increasing its activity. In the case of the A42G and M182T mutant enzymes,
the favorable van der Waals energy term is either compensated (for A42G) or overcome
(for M182T) by unfavorable electrostatic and internal energy terms.
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Table 6.2: Binding affinity data for TEM-1 -lactamase and its mutants with cefotaximea.
Gint

GCoul

GvdW

Gsol

Gelec

Gbind

GvdW

Gelec

Gbind

MIC[29
]
(µg/ml)

a

WT

0.39(0.25)

-30.85(0.32)

-32.34(0.17)

30.40(0.26)

5.09(0.15)

-32.41(0.24)

0

0

0

0.088

G238S

2.47(0.24)

-37.27(0.31)

-46.5(0.15)

39.61(0.25)

8.65(0.15)

-41.67 (0.24)

-14.16

3.56

-9.26

1.410

E104K

1.59(0.24)

-81.78(0.49)

-39.84(0.17)

83.82(0.41)

7.84(0.19)

-36.19 (0.27)

-7.50

2.75

-3.78

0.132

A42G

3.48(0.25)

-15.29(0.31)

-42.77(0.16)

21.43(0.24)

11.77(0.16)

-33.16 (0.24)

-10.43

6.68

-0.75

0.088

M182T

0.55(0.24)

12.53(0.38)

-41.55(0.17)

1.93(0.32)

20.26(0.14)

-26.54 (0.23)

-9.21

15.17

5.87

0.063

Binding affinities are in kcal/mol; Gelec = GCoul +Gpol-sol; The standard errors associated with the averages are given next

to the values.
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2. Structural Properties as observed during MD simulations:

(i) Root Mean Square Deviation (RMSD):

In order to gain insight into the effect of mutations on the structural properties of
cefotaxime bound TEM -lactamase, we first monitored the root mean square deviation
(RMSD) parameter. The average structures of the cefotaxime bound mutant enzymes
from the production run (last 10 ns) were compared to that of wild type average structure.
The average structures of the mutant enzymes were superimposed on the average
structure of wild type enzyme using the coordinates of the main chain atoms (N, CA, and
C atoms according to PDB[34] nomenclature), and the RMSD of the overall structure as
well as of the structural units and of the individual residues were calculated. For
convenience, the region between residues 86 and 118 was named as AS1 (active site
region 1). Similarly, the regions from residues 213-229 and from residues 267 to 271
were named AS2 and AS3 respectively.
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Table 6.3: Summary of the RMS Deviations for different domains of the cefotaxime
bound enzymes.

G238S

E104K

A42G

M182T

Total

0.84

0.70

0.60

0.63

-loop (161-179)

1.27

0.90

0.97

1.08

AS1 (86-118)

1.11

1.07

0.86

0.75

AS2 (213-229)

1.38

1.01

0.93

1.06

AS3 (267-271)

1.72

1.04

0.66

0.50

AS

1.26

1.01

0.90

0.90

The RMSDs are given in Å; AS = -loop + AS1 + AS2 + AS3
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Out of the four mutant structures, the G238S structure was observed to exhibit the
highest structural deviation from the wild type. The overall structural deviation (RMSD=
0.84 Å) as well as the RMSD for the active site region (RMSD = 1.26 Å) for G238S was
found highest among the four mutants (table 6.3). The structural deviation in different
parts of the enzyme, as well as in the active site region of the E104K mutant enzyme was
observed to be second highest after G238S (table 6.3). The -loop, which is a relatively
flexible part of the enzyme, shows the largest structural deviation upon mutation
compared to other regions.
In order to analyze the structural deviation in more detail, we have calculated the
RMSD for the every residue of the mutant enzyme relative to the wild type. As shown in
figure 6.3, three distinct regions in the G238S mutant enzyme (AS1, AS2, and AS3) apart
from -loop show significant structural deviation upon mutation. These four regions of
the enzyme contain most of the residues that define the binding pocket for cefotaxime.
The E104K mutant enzyme, which has the second highest binding affinity after G238S
mutant, has a significant RMSD in these four regions (figure 6.3), however, less in
comparison to the G238S mutant. For the A42G and M182T mutant, the structural
change is less significant compared to the G238S and E104K mutant enzymes, other than
in the -loop, which is a very flexible part of the enzyme.
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Figure 6.3: The RMSD of the residues of the cefotaxime bound mutant enzymes compared to the
corresponding wild type structure.




149


(ii): Hydrogen Bonds between Lactamase and Cefotaxime:

Hydrogen bonds have a critical role to play in stabilizing protein-ligand
complexes and therefore contribute significantly to developing specificity for a substrate.
The most significant hydrogen bonds between cefotaxime and enzyme structures were
examined by analyzing 1000 snapshots taken during the 10 ns of the production
simulation. The enzyme-substrate hydrogen bonds were characterized in terms of
distance between heavy atoms, as reported in the table 6.4.
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Table 6.4: Summary of the average distances between heavy atoms involved in important hydrogen bonding interactions
between cefotaxime and enzymes.

Hydrogen bond

TEM-1

G238S

E104K

A42G

M182T

CEF-O····H-N-ALA237

3.22±0.39

2.92±0.17

3.17±0.45

2.86±0.14

2.93±0.15

CEF-O6····H-N1-ARG244

3.38±0.47

2.88±0.20

2.85±0.19

3.12±0.33

4.73±0.57

CEF-O2····H-N-ASN132

6.16±1.14

3.17±0.31

3.03±0.30

2.91±0.17

3.09±0.31

CEF-O5····H-N-LYS-234

5.96±0.68

4.31±0.27

4.13±0.34

4.25±0.28

4.83±0.28

CEF-O5····H-O-SER-130

6.58±0.60

2.67±0.15

2.71±0.16

2.69±0.15

2.72±0.21

CEF-O5····H-O-SER-235

2.65±0.14

3.13±0.31

2.85±0.21

3.01±0.27

5.22±0.44

CEF-O6····H-O-SER-235

3.94±0.47

2.78±0.17

2.97±0.22

2.87±0.20

4.61±0.42

CEF-O····H-O-SER-70

4.28±0.52

2.94±0.23

3.47±0.53

3.17±0.21

3.12±0.20

CEF-N1-H····O=C-ALA-237

6.14±0.40

3.41±0.28

4.56±1.28

3.37±0.29

3.14±0.26

CEF-N4-H····O=C-PRO-167

4.52±1.55

4.66±0.40

5.40±1.31

5.22±0.84

5.10±0.76

All the distances are given in Å
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The distances given in table 6.4 generally indicate the restructuring of ligand in

the binding pocket upon mutations. However, the changes in the pattern of hydrogen
bonding with cefotaxime upon single point mutations were not found to be a major
contributor to change in binding affinity (table 6.2). Only two interactions involving the
carbonyl oxygen (O) of the ligand (with residues Ala237 and Ser70) are consistently
present within all mutant and wild type structures. These interactions with the carbonyl
oxygen of the ligand help to maintain the reactive center of the cefotaxime in the right
orientation relative to the catalytic residues of the enzyme. Since all parts of the ligand
(-lactam ring and two side chains) can be seen to form hydrogen bonds, all three parts of
the ligand are responsible for binding the substrate within the active site and contribute
towards the specificity. The negatively charged carboxylate group of cefotaxime makes a
number of H-bonds with residues Ser130, Ser235 and Arg244 in the carboxylate group
accommodating pocket and therefore appears to be major contributor to the binding
affinity (see the discussion section). All hydrogen bonding interactions (except CEF-N4-

H····O=C-PRO-167) reported in current study have been found to be present during a
molecular dynamics simulation of cephalothin (another cephalosporin -lactam
antibiotic) bound to TEM-1 -lactamase[167]. The CEF-O5····H-N-LYS-234 hydrogen
bond is particular to the E104K mutant and is not very significant in other structures. The
residue ALA237, which is involved in the formation of the so called “oxyanion
hole”[167], makes two significant interactions with the ligand. The first interaction is

CEF-O····H-N-ALA237, which is very significant in all mutants as well as in the wild
type structures. The second interaction involving ALA237 is CEF-N1H····O=C-ALA-
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237, which is very significant in all mutant structures, but appears to be less significant in
the wild type structure.
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DISCUSSION

None of the four mutant positions examined in this study are present within the
binding region of cefotaxime, as observed in docking calculations. The G238 and E104
are near the cefotaxime binding pocket, however, none of these residues nor were the
mutant residues at these positions found to make any significant contact with docked
structure of cefotaxime. The residues A42 and M182 are far from the binding pocket. It is
therefore not very clear how these four mutations will affect the binding affinity with the
substrate. At the same time, there is no crystal structure available for these mutants in
cefotaxime bound conformation which could give insight into to its resistance
mechanism.
Since wild type -lactamase cannot properly accommodate the cefotaxime in its
binding pocket, structural changes at active site upon mutation have been proposed as the
possible mechanism for developing resistance [161-163]. The G238S mutation causes a
maximum increase in catalytic efficiency compared to other three single point mutations,
and therefore it has been center of attraction. Considering the physiological implications
of the G238S mutation, an experimental study was performed to correctly identify the
role of Ser[161]. In the experimental study, the hydroxyl group of Ser was not found to
make any direct contribution towards the binding affinity for cefotaxime through
hydrogen bonding, and therefore it was suggested the restructuring at the active site is the
possible reason for the increase in the catalytic activity of -lactmase upon G238S
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mutation[161]. However, it is not clear from the experiment that what type of structural
changes take place upon this mutation.
As shown is the figures 6.3 and figure 6.4, the active site restructuring is evident
in G238S mutant enzymes, which is consistent with the experimental studies[161-163].
Most significant restructuring was found to takes place in -loop. As shown in figure 6.4,
the -loop in G238S mutant enzyme is opening up and providing more space for the
ligand to fit into the binding pocket. The significant structural change in other part of
active site (AS1, AS2, and AS3) were also observed apart from structural changes in loop (figure 6.3 and 6.4), which aid into the ability of enzyme to bind better to
cefotaxime. No hydrogen bonding interaction with hydroxyl group of Ser238 residue to
any part of the cefotaxime was observed during the MD simulation. And therefore, the
entire increase in binding affinity is coming from the active site restructuring caused by
G238S mutation, which is in agreement with the previous experimental observation[161].
The structural changes in the binding pocket of E104K mutant enzyme are also
very significant. In the case of E104K mutation, the most significant structural changes
were observed in AS1, AS2 and AS3 regions (figure 6.3 and 6.4), along with significant
structural changes in -loop. As mentioned earlier, these structural changes in active site
region appear to help in increasing the binding affinity of the E104K mutant enzyme for
the cefotaxime. The structural changes in active site region are less significant for the
A42G and M182T mutants, which does not show increase in catalytic efficiency (figure
6.3 and 6.4). The correlation between structural changes at active site and increase in
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catalytic activity for cefotaxime indicate that the restructuring of active site is a general
mechanism for increasing the resistance against cefotaxime within TEM -lactamase.
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Figure 6.4: Active site region of the averaged structures of the mutant enzymes superimposed
over wild type. Green = wild type; Red = Mutants. Ligand structures belong to mutant enzymes.
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The C2 atom of the dihydrothiazine ring of cefotaxime can flip between up and
down conformations with respect to the plane formed by C, S, and C3 atoms of the ring,
and therefore the cefotaxime can adopt two distinct conformations based on the
orientation of C2 atom. These conformations of cefotaxime are termed as C2-up and C2down conformations. Majority of the crystal structures of third generation cephalosporin

-lactam antibiotics bound to -lactamase have been reported to exhibit the C2-down
conformation[167]. In a previous theoretical study, it has been suggested that C2-down
conformation in cephalosporin is energetically favored[167]. It has also been suggested
that the preference between C2-up and C2-down conformations is mainly governed by
the conformational preferences of antibiotic side groups[167, 186].
In the present study, we have further rationalized the structural implications of the
C2-down conformation. We have observed that in G238S mutant enzyme which has the
highest activity against cefotaxime, the cefotaxime adopts C2-down conformation 98.6%
time of total 10ns production run. For the M182T mutant enzyme, which has lowest
activity among the mutant enzymes, the C2-up conformation was found to be populated
during 100% time of the production simulation length. As shown in figure 6.5, in the case
of C2-down conformation, the two side chain of cefotaxime adopts an extended
conformation relative to the C2-up conformation. This can be thought as an indicative of
the volume difference between active sites of these two mutant enzymes. The G238S
mutant enzyme is providing an extended binding pocket compared to M182T mutated
enzyme which help accommodating the cefotaxime better. The population of C2-down
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conformation for E104K, A42G and wild type structures were found to be 44.3%, 6.2%
and 17.4% respectively.
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Figure 6.5: The superimposition of average ligand structures from G238S mutant enzyme
simulation (blue) and M182T mutant enzyme simulation (green). The ligand bound in G238S
mutant enzyme’s pocket can be seen as adopting extended conformation compared to the ligand
bound to M182T mutant enzyme.
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As mentioned earlier regarding MM-GBSA, apart from being computationally
efficient and reliable in predicting the relative binding affinities, the MM-GBSA binding
affinity can be efficiently decomposed into per-residue contributions which can provide
further insight into binding mechanism. In present study, we have decomposed the total
binding affinity as well as van der Waals and electrostatic part of binding affinity into its
per-residue contributions.
For the wild type structure, the major contribution to the binding affinity comes from
the residue R244 which accommodates the carboxylic goup attached to the
dihydrothiazine ring of cefotaxime. The R244 contribute towards binding affinity
primarily through the electrostatic component (figure 6.6). The S235 is the other residue
which significantly contributes (~2 kcal/mol) towards binding affinity through
electrostatic component. The residues S70, Y105, S130, N132, V216, G326, and A237
contribute through van der Waals interaction (figure 6.6).
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Figure 6.6: The per-residue decomposition of the MM-GBSA binding free energy of wild-type
enzyme for cefotaxime. The first graph represents the per-residue decomposition of the total
binding free energy. The second graph represents per-residue decomposition of electrostatic
component (Columbic and electrostatic solvation) of binding free energy and the third graph
represents the per-residue decomposition of van der Waals component of binding free energy.
Per-residue contribution of ligand residue is not represented in the above graphs.
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We further analyzed the differential binding affinities [G(mutant) = G(mutant) -

G(wild-type) ] of mutant enzymes for cefotaxime compared to wild type enzyme. The
differential increase in binding affinity of G238S mutant enzyme mainly come from the
residues Y105, N170, K234, A237 and S238 (figure 6.7). Out of these residues, the
Y105, N170, A237 and S238 contribute towards differential stabilization through van der
Waals interactions (figure 6.8). The residue K234 increases differential binding affinity
through electrostatic term (figure 6.9). In the case of E104K mutant enzyme, residues
K104, Y105, N170 and A237 contribute towards differential stabilization through van der
Waals interactions (figure 6.8). In E104K mutant enzyme, the K234 contributes
significantly through electrostatic interaction (figure 6.9). The R244 position in E104K
mutant is less differentially destabilizing (3.64 kcal/mol) compared the G238S mutant
enzyme (4.08 kcal/mol). The R244 position in A42G mutant enzyme contributes more
towards differential destabilization (5.11 kcal/mol) compared to E104K and G238S
mutant enzymes, but less compared to M182T mutant enzyme where it is highest with the
value of 7.4 kcal/mol (figure 6.7). R244 also contributes in differential stabilization
through van der Waals interactions for all the mutant enzymes (figure 6.8). In the case of
A42G mutant enzyme, the contributions to differential binding affinity though van der
Waals interactions come from residues P167, N170, A237, and R244 (figure 6.8). The
residues N132 and K234 contribute through electrostatic interactions for A42G mutated
enzyme (figure 6.9). The residues of M182T mutant enzyme make several differential
stabilizing and destabilizing contributions to binding affinity. The differentially
stabilizing contributions from M69, S70, N132, P167, N170, K234 and A237 are
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overcomed by differential destabilizing contributions from S130, V216, S235 and R244.
The S130 makes destabilizing interaction compared to wild type enzyme, in mutant
structures.
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Figure 6.7: Per-residue decomposition of differential binding free energy of the mutant enzymes
for cefotaxime, compared to the wild type binding free energy. Per-residue contribution of ligand
residue is not represented in the above graphs.
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Figure 6.8: Per-residue decomposition of differential van der Waals component of binding free
energy of the mutant enzymes for cefotaxime, compared to the wild type affinity. Per-residue
contribution of ligand residue is not represented in the above graphs.
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Figure 6.9: Per-residue decomposition of differential electrostatic component of binding free
energy of the mutant enzymes for cefotaxime, compared to the wild type affinity. Per-residue
contribution of ligand residue is not represented in the above graphs.
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In order to catalytically hydrolyze the cefotaxime, the -lactamase evolves by
expanding its pre-existing ability to catalytically hydrolyze the benzylpenicillin. Since,
the mutants G238S and E104K retain some activity against benzylpenicillin while
gaining the activity against the cefotaxime[187], the first step of evolution can be looked
as the process of increasing its functional promiscuity. According to one of the proposed
mechanism of the structural change in protein while acquiring the promiscuity[188, 189],
the protein becomes more flexible upon mutations and can shift between alternate
conformations without any significant free energy change.

On the potential energy

diagram (figure 6.10), we can think of two potential energy well for the alternate
structures. The well A corresponds to the native conformation and B corresponds to the
alternate conformation which is required for the new function. According to the
mechanism of increase in flexibility[188, 189], both conformations A and B become
almost equal in energy with very low energy barrier between them(case I in figure 6.10),
and therefore, there is no significant energetic penalty in conformational change.
However, usually only one type of beta-lactam antibiotic is used in the treatment bacterial
infection, and therefore bacteria has no advantage in evolving for promiscuity. Therefore,
the observed promiscuity may be just a side effect. In this case, there is a possibility that
the conformation B becomes more stable compared to the conformation A, as suggested
in previous studies[188, 190, 191]. This can be represented as the case II and III in figure
6.10 (G23S, E104K and M182T mutations have been shown to increase the fold stability
of -lactamase[192, 193]). This will result into pre-adopted the conformation of enzyme
which can preferentially bind to the new ligand.
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In order to address these possibilities, we have analyzed the structural properties
of the unbound wild type and mutant enzymes during molecular dynamics simulation
(figure 6.11 and figure 6.12). In brief, we did not observe any considerable change in
flexibility (as quantified by root mean fluctuation of CA atoms) within the binding region
of the unbound mutant enzymes. However, for G238S we have observed considerable
change in the structure of active site region during the course of the production
simulation. Similarly for E104K, we observed significant structural change in AS1
region. Since the time scale over which conformational transition between state A and B
takes place, or the time scale of the conformational transition from state A to B is not
known, our observation based on the ns time scale simulation is just an indicative of what
is most likely and does not necessarily provide a conclusive evidence about the
mechanism regarding structural change. In the case of ligand bound structures, these
conformational changes are accelerated in molecular dynamics simulation by the
presence of the ligand in the binding pocket of enzyme. One more thing should be
noticed here that, in case of whatever mechanism among the above discussed possibilities
is true, the free energy difference between bound and unbound conformer of enzyme will
be very small. And therefore, our assumption that the change in internal energy of
enzyme is negligible upon ligand binding (and therefore no separated unbound enzyme
trajectory was used in MM-GBSA free energy calculation) is reasonably correct.
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Figure 6.10: The figure depicts the potential energy profile of two conformation of an enzyme. The case I depicts evolution by increasing
the flexibility. Case II and III depict evolution by differential stabilization of alternate conformation (B) upon mutation.
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Figure 6.11: The root mean square deviation (RMSD) of the residues of the unbound mutant
enzymes compared to the unbound wild type structure.
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Figure 6.12: The root mean square fluctuation (RMSF) for unbound mutant enzymes. The RMSF
of wild type enzymes are represent as dotted line in each graph.
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CONCLUSIONS

In the present work, we have been able to successfully separate the beneficial
mutations (G238S and E104K) from non-beneficial mutations (A42G and M182T) at the
first step of beta-lactamase evolution within a background of selective pressure. We have
further identified the structural rearrangement within active site of enzyme upon mutation
as the possible mechanism, which helps increasing its activity against cefotaxime. The
active site rearrangement could be a general mechanism for increasing its activity against
cefotaxime upon any combinations of above discussed single point mutations. The
energetic calculations in combination of structural analyses presented in current
manuscript can be helpful in development of new generation antibiotics.
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APPENDIX A

SUPPLEMENTARY INFORMATION FOR CHAPTER ONE

The following tables contain binding affinity data for all the native as well as distorted
complexes used in the present study. The mean energies are in kcal/mol with a
corresponding standard error in following column.

Table AA.1: 1D7J.pdb
Experimental binding affinity = -4.5 kcal/mol[194]
RMSD (Å)

H

SE

-TS

SE

Native
Complex
Native
Complex
(Seed 1)
Native
Complex
(Seed 2)
Native
Complex
(Seed 3)
Native
Complex
(Seed 4)
Native
Complex
(Seed 5)
Native
Complex
(Seed 6)
0.727137

-22.848108

0.106429

-12.234015

0.29289

-10.614093

0.31162748

-23.780147

0.142172

-11.6127

0.309376

-12.1674

0.34048

-20.768952

0.089946

-11.1888

0.28955

-9.58016

0.303199

-25.298954

0.08575

-11.3174

0.286847

-13.9815

0.29939

-26.442611

0.128179

-12.4779

0.343909

-13.9647

0.367019

-24.100785

0.074263

-11.775

0.266783

-12.3258

0.276926

-26.572411

0.062111

-12.1606

0.400221

-14.4118

0.405012

-29.104891

0.061766

-13.260568

0.318348

-15.844323

0.32428458

0.94636

-23.226925

0.120222

-11.264962

0.295794

-11.961963

0.31929206

0.995319

-24.137968

0.081314

-11.832568

0.254813

-12.3054

0.26747267

1.00042

-28.074345

0.089772

-11.880897

0.393848

-16.193448

0.40394957

1.01942

-22.712315

0.089827

-11.508942

0.255019

-11.203373

0.27037674

1.03671

-28.120439

0.073803

-12.552111

0.411703

-15.568328

0.41826576

1.10401

-28.239986

0.092998

-12.617528

0.3718

-15.622458

0.38325431
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G

SE

1.14355

-30.775795

0.068723

-12.947574

0.303465

-17.828221

0.31114925

1.2171

-23.800483

0.065934

-12.013633

0.291272

-11.78685

0.29864137

1.29314

-23.622737

0.057321

-11.618821

0.257236

-12.003916

0.26354517

1.31656

-22.686519

0.07942

-11.618179

0.271738

-11.06834

0.28310612

1.35181

-30.483437

0.085305

-12.884116

0.312325

-17.599321

0.32376511

1.35551

-23.431978

0.08279

-12.093503

0.342081

-11.338475

0.35195681

1.39959

-20.678426

0.075693

-11.376432

0.353779

-9.301994

0.36178586

1.60048

-27.449878

0.054735

-13.054362

0.308129

-14.395516

0.31295271

1.60886

-20.094795

0.092221

-11.057536

0.291887

-9.037259

0.30610902

1.89885

-24.909765

0.066091

-12.794185

0.332962

-12.11558

0.33945797

2.02217

-26.007245

0.115615

-11.989032

0.325591

-14.018213

0.3455088

2.14163

-24.85456

0.088305

-11.944766

0.294796

-12.909794

0.30773764

2.305

-29.57228

0.086867

-12.806944

0.373642

-16.765336

0.38360686

2.35808

-23.018212

0.090051

-11.740598

0.261643

-11.277614

0.27670606

2.36868

-27.597348

0.059554

-13.287617

0.327524

-14.309731

0.33289435

2.4252

-23.060419

0.074957

-11.809785

0.286352

-11.250634

0.29600003

2.47242

-28.324937

0.091615

-12.385316

0.342926

-15.939621

0.35495288

2.54512

-26.397179

0.081813

-13.581084

0.359306

-12.816095

0.3685026

2.62652

-20.837078

0.085629

-11.369897

0.257218

-9.467181

0.27109671

2.63266

-26.974243

0.063206

-12.330124

0.309606

-14.644119

0.31599189

2.67609

-31.272223

0.075428

-13.083372

0.297734

-18.188851

0.3071399

2.726

-23.625401

0.106544

-11.847169

0.302728

-11.778232

0.32092969

2.76417

-26.055091

0.116597

-12.382952

0.338356

-13.672139

0.35788216

2.8176

-28.618008

0.086693

-13.056646

0.316958

-15.561362

0.32860014

2.88108

-23.91035

0.073399

-11.614882

0.307619

-12.295468

0.31625443

2.92338

-23.691874

0.097685

-11.505514

0.347824

-12.18636

0.36128091

2.92668

-23.817504

0.076087

-12.36109

0.330136

-11.456414

0.33879051

2.93432

-28.502144

0.078271

-12.573225

0.338688

-15.928919

0.3476146

3.02225

-22.09256

0.087504

-11.768281

0.282365

-10.324279

0.29561283

3.16262

-24.372344

0.092438

-11.150671

0.32378

-13.221673

0.3367169

3.18588

-19.769059

0.063637

-12.367648

0.29524

-7.401411

0.30202041

3.25012

-30.140235

0.078332

-12.234614

0.321028

-17.905621

0.33044648

3.59879

-27.142137

0.074163

-12.743566

0.354728

-14.398571

0.36239772

3.60455

-20.389953

0.069278

-11.958911

0.307695

-8.431042

0.31539761

3.62044

-25.040826

0.093989

-11.84351

0.260247

-13.197316

0.27669917

3.62721

-20.505301

0.091731

-11.073104

0.302794

-9.432197

0.31638392

3.78113

-31.258151

0.07534

-12.218651

0.348811

-19.0395

0.35685463

3.85385

-37.983068

0.073363

-13.434247

0.340704

-24.548821

0.34851305

3.92826

-23.388317

0.090614

-12.210879

0.33814

-11.177438

0.35007079
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3.95457

-26.429204

0.106418

-11.693008

0.316483

-14.736196

0.33389561

4.01356

-25.635705

0.124947

-11.762184

0.314326

-13.873521

0.3382493

4.01398

-25.399803

0.041945

-12.499314

0.368569

-12.900489

0.3709481

4.30388

-23.229647

0.106902

-12.091069

0.35482

-11.138578

0.37057424

4.54993

-22.570574

0.094286

-11.50836

0.277111

-11.062214

0.29271207

4.54993

-33.625002

0.068443

-12.403019

0.361479

-21.221983

0.3679015

4.65814

-24.498047

0.088477

-11.030539

0.306459

-13.467508

0.31897539

4.80338

-22.901148

0.07827

-12.204368

0.363264

-10.69678

0.37160049

4.93072

-35.327257

0.080185

-12.752146

0.365555

-22.575111

0.37424603

5.00367

-24.026303

0.072055

-12.054461

0.29344

-11.971842

0.30215717

5.09211

-28.549311

0.064731

-12.586399

0.397159

-15.962912

0.40239952

5.17215

-23.525299

0.098761

-11.957806

0.324861

-11.567493

0.33954146

5.27617

-25.177852

0.132369

-11.707924

0.322689

-13.469928

0.34878323

5.28545

-38.737094

0.079867

-12.883146

0.426942

-25.853948

0.43434803

5.28545

-32.543533

0.056519

-14.652174

0.444235

-17.891359

0.44781596

SE

G

SE

Table AA.2: 2IFB.pdb
Experimental binding affinity = -11.10kcal/mol[195]
RMSD (Å)

H

SE

-TS

Native
Complex
Native
Complex
(Seed 1)
Native
Complex
(Seed 2)
Native
Complex
(Seed 3)
Native
Complex
(Seed 4)
Native
Complex
(Seed 5)
Native
Complex
(Seed 6)
1.63158

-82.576491

0.140441

-20.83978

0.723606

-61.736711

0.73710876

-88.9955

0.102374

-22.8457

0.705867

-66.1498

0.713252

-89.143

0.126653

-21.6883

0.711314

-67.4547

0.722502

-88.3872

0.094885

-23.5682

0.597884

-64.819

0.605366

-84.17

0.110569

-21.3652

0.635381

-62.8047

0.64493

-88.6999

0.107572

-21.8507

0.651943

-66.8492

0.660758

-89.0827

0.124648

-22.0988

0.611515

-66.9839

0.62409

-87.403541

0.106609

-19.802318

0.636335

-67.601223

0.64520362

1.68217

-84.040073

0.111055

-23.08527

0.691211

-60.954803

0.70007561
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1.70679

-90.970469

0.105573

-21.709466

0.593978

-69.261003

0.60328726

1.73156

-93.299519

0.12027

-23.083204

0.632436

-70.216315

0.64377028

1.74247

-89.380323

0.125565

-23.522834

0.684946

-65.857489

0.69636025

1.75455

-81.586421

0.0832

-22.670964

0.766721

-58.915457

0.77122197

1.79758

-96.454782

0.133763

-21.992056

0.591305

-74.462726

0.60624594

1.8153

-93.393452

0.119714

-23.449942

0.662083

-69.94351

0.67281895

1.9133

-99.22965

0.320935

-22.692002

0.562341

-76.537648

0.64747716

1.94027

-92.597268

0.12793

-21.96739

0.626062

-70.629878

0.63899899

1.96179

-84.076926

0.101184

-22.419776

0.618029

-61.65715

0.62625717

1.9942

-73.541762

0.090855

-21.03236

0.652697

-52.509402

0.65899014

2.02203

-100.816766

0.126299

-21.590436

0.653889

-79.22633

0.66597467

2.03971

-68.723123

0.112619

-21.13106

0.593029

-47.592063

0.60362773

2.06049

-85.714243

0.114675

-21.103861

0.680453

-64.610382

0.69004829

2.09275

-96.32263

0.129707

-25.065814

0.675661

-71.256816

0.68799832

2.11452

-106.690005

0.126044

-22.118222

0.612135

-84.571783

0.62497708

2.17659

-80.009733

0.125102

-19.397465

0.681164

-60.612268

0.69255679

2.19515

-94.841529

0.126398

-19.574188

0.589514

-75.267341

0.60291227

2.21715

-105.187981

0.118536

-22.184662

0.699369

-83.003319

0.7093432

2.21877

-90.397542

0.132171

-22.187276

0.595093

-68.210266

0.60959401

2.26667

-107.189598

0.137167

-24.537826

0.721418

-82.651772

0.73434237

2.2701

-85.459632

0.10038

-21.63543

0.694073

-63.824202

0.70129414

2.3558

-91.746652

0.121801

-21.388704

0.707727

-70.357948

0.7181316

2.36088

-86.45386

0.1269

-22.795318

0.576737

-63.658542

0.59053296

2.51365

-103.358409

0.127842

-23.51055

0.598073

-79.847859

0.61158392

2.54569

-80.40344

0.092602

-19.694432

0.632513

-60.709008

0.63925568

2.65945

-99.36166

0.119888

-20.471614

0.652752

-78.890046

0.66367033

2.6645

-55.014837

0.071759

-21.958306

0.623472

-33.056531

0.62758799

2.89208

-96.312517

0.161559

-20.420263

0.638538

-75.892254

0.65865931

3.01207

439.87679

0.43578

-27.41748

0.808431

467.29427

0.91840345

3.10099

-52.771295

0.143781

-19.97204

0.553022

-32.799255

0.57140731

3.26106

-95.904107

0.161661

-23.089934

0.646343

-72.814173

0.66625337

3.28317

-105.132834

0.140313

-23.364504

0.615624

-81.76833

0.63141163

3.53058

-92.251358

0.113434

-22.68901

0.622929

-69.562348

0.63317281

3.59118

-81.792542

0.104355

-20.485326

0.656456

-61.307216

0.66469876

3.62397

-94.40146

0.137312

-22.980728

0.688621

-71.420732

0.70217766

3.71905

-93.27221

0.229647

-23.702602

0.634049

-69.569608

0.6743559

3.79633

-99.541384

0.149661

-22.49114

0.605194

-77.050244

0.62342457

3.91179

-95.643914

0.165691

-25.048784

0.701856

-70.59513

0.72114863

3.94326

-93.254905

0.154406

-20.88737

0.724675

-72.367535

0.74094201
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3.95442

-95.814892

0.103392

-18.761516

0.702237

-77.053376

0.70980752

4.05531

-76.701267

0.092901

-20.343028

0.570442

-56.358239

0.57795733

4.28202

-89.560554

0.117131

-23.13717

0.693829

-66.423384

0.70364647

4.45364

-101.297345

0.156083

-23.469002

0.661901

-77.828343

0.68005502

4.48865

-90.205262

0.109447

-21.996486

0.594516

-68.208776

0.60450634

4.65791

-99.775825

0.132961

-21.103592

0.659194

-78.672233

0.6724696

5.02984

-148.777266

0.17957

-23.506338

0.756159

-125.27093

0.77718841

5.03896

-100.867596

0.110917

-25.253204

0.695467

-75.614392

0.70425629

5.10036

-100.40455

0.251971

-22.139368

0.686634

-78.265182

0.73140661

5.27728

497.116381

0.452732

-27.647506

0.832169

524.763887

0.94734973

5.3847

-124.639752

0.151218

-20.733484

0.649273

-103.90627

0.66665007

G

SE

Table AA.3: CYH.pdb
Experimental binding affinity = na
RMSD (Å)

H

Native
Complex
Native
Complex
(Seed 1)
Native
Complex
(Seed 2)
Native
Complex
(Seed 3)
Native
Complex
(Seed 4)
Native
Complex
(Seed 5)
Native
Complex
(Seed 6)
1.13178

-72.504295

0.184614

-13.021546

0.596138

-59.482749

0.62406958

-72.946432

0.152556

-14.4066

0.394934

-58.5399

0.423375

-75.639224

0.13386

-16.3465

0.404123

-59.2927

0.425716

-76.726581

0.178919

-15.7172

0.424441

-61.0094

0.460611

-65.251099

0.181179

-16.03

0.410116

-49.2211

0.448354

-66.404692

0.177064

-15.2126

0.427673

-51.1921

0.462878

-72.229057

0.168798

-15.4262

0.406135

-56.8029

0.439816

-72.436587

0.166713

-14.570021

0.456958

-57.866566

0.48641941

1.37547

-67.176187

0.22934

-15.440094

0.455184

-51.736093

0.50969531

1.41169

-69.543555

0.128052

-15.90176

0.384162

-53.641795

0.40494167

1.46908

-67.824121

0.156883

-15.603714

0.391649

-52.220407

0.4219019

SE

-TS

SE
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1.51354

-68.755813

0.144426

-15.409556

0.395624

-53.346257

0.42116175

1.53332

-63.849118

0.15772

-15.60654

0.374646

-48.242578

0.40649136

1.54545

-64.498715

0.281122

-14.871003

0.430185

-49.627712

0.51389562

1.54928

-70.947836

0.201498

-14.997989

0.403681

-55.949847

0.45117601

1.55185

-68.791695

0.13362

-16.442832

0.370586

-52.348863

0.39393945

1.59341

-66.509285

0.279801

-14.911707

0.424803

-51.597578

0.508671

1.6167

-73.753803

0.15531

-16.300714

0.451978

-57.453089

0.47791768

1.63438

-64.560639

0.158279

-15.748215

0.427887

-48.812424

0.45622311

1.74182

-57.694064

0.129458

-15.909445

0.388433

-41.784619

0.40943811

1.78044

-66.024259

0.205231

-13.236777

0.530053

-52.787482

0.5683977

1.82653

-56.122109

0.1812

-13.662595

0.411374

-42.459514

0.44951308

1.84325

-62.845369

0.167325

-14.4913

0.354704

-48.354069

0.39218947

2.18595

-51.958679

0.268069

-14.706677

0.415701

-37.252002

0.49463958

2.19079

-63.362739

0.136345

-15.156098

0.377844

-48.206641

0.40169148

2.20065

-67.860382

0.191501

-15.069832

0.396147

-52.79055

0.44000577

2.23812

-57.067616

0.125088

-13.321246

0.356082

-43.74637

0.37741409

2.27282

-44.866552

0.12635

-13.636352

0.367704

-31.2302

0.38880658

2.30014

-62.794966

0.234494

-14.205994

0.425472

-48.588972

0.48581258

2.34822

-60.436649

0.146103

-14.48874

0.394936

-45.947909

0.42109444

2.49166

-75.28656

0.186323

-17.130778

0.442547

-58.155782

0.48017091

2.56071

-73.569136

0.248487

-14.750524

0.430325

-58.818612

0.49691588

2.78955

-66.230098

0.141338

-14.428212

0.513952

-51.801886

0.53303198

2.83144

-54.846609

0.100728

-13.309275

0.333642

-41.537334

0.34851559

2.88991

-55.142966

0.115375

-14.220224

0.418249

-40.922742

0.43387051

2.89235

-61.814532

0.177124

-15.299197

0.435387

-46.515335

0.47003697

2.94251

-69.093995

0.159412

-14.473964

0.420265

-54.620031

0.44948288

3.16081

-69.335757

0.169076

-15.898354

0.436908

-53.437403

0.4684819

3.16152

-90.671605

0.194524

-18.213178

0.450694

-72.458427

0.49088152

3.19457

-58.469803

0.200234

-14.325384

0.409412

-44.144419

0.45575414

3.2648

-78.672663

0.258812

-16.2513

0.470198

-62.421363

0.53672135

3.26663

-52.546878

0.157117

-14.513088

0.407822

-38.03379

0.43704066

3.29871

-64.436161

0.193021

-14.893625

0.448116

-49.542536

0.48791911

3.38614

-52.816837

0.097635

-14.624124

0.384218

-38.192713

0.39642914

3.4039

-79.807412

0.195569

-15.150851

0.52409

-64.656561

0.55939035

3.43291

-62.895712

0.179222

-14.502203

0.431959

-48.393509

0.46766345

3.45099

-59.898315

0.113628

-14.08567

0.451812

-45.812645

0.46588132

3.45564

-59.342291

0.255626

-14.040714

0.430582

-45.301577

0.50074496

3.54851

-76.932364

0.205727

-13.579596

0.329099

-63.352768

0.38811049

3.58574

-65.95536

0.165283

-14.195246

0.357671

-51.760114

0.39401398
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3.74401

776.474389

0.606621

-22.196038

0.531384

798.670427

0.80644776

3.74923

-51.601125

0.139221

-12.731389

0.388548

-38.869736

0.41273725

3.78018

-60.890997

0.155957

-14.34745

0.438867

-46.543547

0.46575404

3.87309

-60.909328

0.188306

-14.699614

0.438848

-46.209714

0.47754237

3.91271

-58.266693

0.239126

-13.386887

0.415999

-44.879806

0.47982957

3.9397

-58.599186

0.15196

-14.31241

0.456195

-44.286776

0.48083856

3.96144

-61.664402

0.199895

-15.757938

0.412884

-45.906464

0.45872782

4.00102

-70.132314

0.161315

-14.788016

0.493494

-55.344298

0.51919058

4.01201

-72.569342

0.186445

-14.270854

0.467015

-58.298488

0.50285659

4.07071

-55.831468

0.183432

-14.233333

0.421981

-41.598135

0.46012527

4.11951

-61.900133

0.158146

-13.878261

0.420309

-48.021872

0.44907662

4.13919

-64.89583

0.187843

-14.71405

0.399475

-50.18178

0.44143546

4.22332

-64.09401

0.116148

-13.302229

0.45705

-50.791781

0.47157721

4.23581

-72.310455

0.190888

-16.996134

0.490937

-55.314321

0.52674222

4.32026

-57.37377

0.195317

-13.159721

0.369103

-44.214049

0.4175952

4.32995

-65.970188

0.217471

-15.86731

0.399915

-50.102878

0.45522043

4.49795

-64.158556

0.121912

-15.366929

0.446892

-48.791627

0.4632224

4.52025

-62.490028

0.188912

-15.478686

0.385291

-47.011342

0.42911176

4.5486

-59.649844

0.137253

-12.483058

0.373613

-47.166786

0.39802646

4.55619

-79.588005

0.183701

-17.47261

0.406622

-62.115395

0.44619223

4.63167

-46.803554

0.07824

-12.957751

0.34089

-33.845803

0.34975347

4.72722

-62.210026

0.120516

-15.202684

0.504662

-47.007342

0.51885243

5.08618

-46.676725

0.187619

-13.614219

0.403738

-33.062506

0.4452025

5.1038

-63.35938

0.227101

-14.408036

0.472259

-48.951344

0.52402617

5.2054

-70.418545

0.182135

-15.30067

0.484442

-55.117875

0.51754923

5.45163

-52.505185

0.122802

-13.866607

0.384609

-38.638578

0.40373805

5.49467

-74.758649

0.197295

-13.826075

0.443942

-60.932574

0.48580842

5.71442

-70.399933

0.130263

-15.200013

0.421622

-55.19992

0.44128626

5.72121

-56.413346

0.20399

-14.602263

0.458998

-41.811083

0.50228586

Table AA.4: 1LKK.pdb
Experimental binding affinity = -9.4 kcal/mol[196]
RMSD (Å)
Native
Complex
Native
Complex

H

SE

-TS

G

SE

-408.031634

0.468764

-31.850002

0.783489

-376.181632

0.91301407

-402.765

0.459208

-35.8837

0.885772

-366.881

0.901946
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SE

(Seed 1)
Native
Complex
(Seed 2)
Native
Complex
(Seed 3)
Native
Complex
(Seed 4)
Native
Complex
(Seed 5)
Native
Complex
(Seed 6)
1.90092

-426.022

0.383204

-33.6811

0.791783

-392.341

0.778992

-384.485

0.327608

-31.0035

0.722331

-353.481

0.687956

-397.089

0.458736

-36.7866

0.889952

-360.302

0.903607

-441.057

0.386349

-37.7204

0.856179

-403.337

0.813368

-424.532

0.398933

-30.3466

0.72882

-394.186

0.762562

-434.634573

0.386899

-30.5544

0.715971

-404.080173

0.81382142

1.97673

-401.330277

0.409102

-33.15177

0.73248

-368.178507

0.83898236

1.99723

-330.40225

0.345046

-31.411662

0.716073

-298.990588

0.79486935

2.04713

-312.299569

0.492667

-29.374196

0.684752

-282.925373

0.84356747

2.0679

-329.166521

0.413248

-24.146466

0.618683

-305.020055

0.74400441

2.08153

-397.471066

0.388194

-34.15737

0.742678

-363.313696

0.83801265

2.12182

-441.920499

0.366296

-27.981068

0.678582

-413.939431

0.77113312

2.14177

-365.41782

0.385113

-30.719786

0.749067

-334.698034

0.84226682

2.17664

-349.017405

0.355098

-27.078888

0.615466

-321.938517

0.71055822

2.17715

-307.235405

0.411072

-30.117632

0.674032

-277.117773

0.78949308

2.18567

-412.574664

0.370309

-32.219768

0.72478

-380.354896

0.81390098

2.19617

-452.921137

0.363477

-33.574978

0.770171

-419.346159

0.85163308

2.2347

-400.197734

0.361969

-31.581118

0.758307

-368.616616

0.84026845

2.24453

-389.461276

0.44494

-30.219538

0.699784

-359.241738

0.82925825

2.26688

-356.207677

0.353324

-31.61191

0.756866

-324.595767

0.8352748

2.26905

-271.085204

0.299422

-27.392306

0.667361

-243.692898

0.73145351

2.34117

-379.833143

0.412058

-29.481956

0.708933

-350.351187

0.81998646

2.34677

-432.544819

0.365294

-34.008196

0.758809

-398.536623

0.84215842

2.37786

-418.453018

0.376857

-32.24299

0.709557

-386.210028

0.80342538

2.49083

-374.18002

0.410646

-29.09577

0.719748

-345.08425

0.82865392

2.53137

-331.627744

0.376264

-25.864672

0.597587

-305.763072

0.7061762

2.98302

-351.042979

0.404677

-31.969986

0.745716

-319.072993

0.84844318

3.02828

-394.142397

0.53847

-28.606912

0.718356

-365.535485

0.89776683

3.0729

-308.079851

0.314229

-25.902436

0.629211

-282.177415

0.70331099

3.14652

-292.323132

0.401918

-26.964874

0.651705

-265.358258

0.76567453

3.36055

-202.940498

0.234737

-30.408366

0.690806

-172.532132

0.72959879

3.38045

-377.441278

0.414656

-34.604154

0.813012

-342.837124

0.91264895
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3.53564

-263.39855

0.3273

-33.2576

0.770529

-230.14095

0.83716201

3.63149

-338.956622

0.405783

-31.176214

0.741415

-307.780408

0.84519586

3.69535

-327.502626

0.383693

-29.078828

0.697055

-298.423798

0.79567958

3.69535

-330.258913

0.365048

-30.743366

0.779798

-299.515547

0.86101392

3.72934

-289.638828

0.461626

-27.568898

0.662551

-262.06993

0.80750999

3.80303

220.472275

0.51475

-34.863926

0.839889

255.336201

0.98507923

3.81042

-286.153795

0.362164

-31.65688

0.720964

-254.496915

0.80681587

3.81885

297.752297

0.438094

-29.413034

0.690592

327.165331

0.81782863

4.09913

-337.648583

0.382286

-26.231868

0.66847

-311.416715

0.77006151

4.30994

-265.378111

0.312514

-28.35867

0.669752

-237.019441

0.7390756

4.41148

-234.031536

0.33355

-26.235268

0.607324

-207.796268

0.69289108

4.47046

-319.466105

0.397137

-26.413628

0.685683

-293.052477

0.79238815

4.50301

-183.239058

0.239057

-24.611356

0.642895

-158.627702

0.68590249

4.51171

-359.857021

0.35493

-24.742554

0.616617

-335.114467

0.71147159

4.59425

-356.811193

0.615526

-25.218368

0.734108

-331.592825

0.95801191

4.61434

-133.009451

0.239126

-24.87123

0.610689

-108.138221

0.6558371

4.78448

-288.010957

0.305855

-26.797566

0.627025

-261.213391

0.69764434

4.82685

-298.304524

0.318057

-29.17018

0.732261

-269.134344

0.79835232

4.83481

-283.978584

0.302669

-27.783036

0.6913

-256.195548

0.75465503

4.84627

-247.791036

0.325918

-24.290476

0.626806

-223.50056

0.70647598

4.91509

-231.522089

0.328104

-29.61275

0.710314

-201.909339

0.78243096

5.03114

-317.891888

0.359395

-29.362038

0.665615

-288.52985

0.75644438

5.12871

-248.314404

0.317311

-35.354424

0.813306

-212.95998

0.8730137

5.24466

296.727617

0.912275

-38.836992

0.899993

335.564609

1.28149642

5.31919

-305.910833

0.311547

-28.608418

0.681719

-277.302415

0.74953474

5.35494

-288.353479

0.751766

-29.309116

0.697327

-259.044363

1.0253863

5.44282

-234.776046

0.321624

-37.534808

0.928258

-197.241238

0.98239753

5.73289

244.634397

0.500866

-33.903114

0.870036

278.537511

1.00390706

6.22638

285.867282

0.5274

-27.680684

0.631615

313.547966

0.82285373

Table AA.5: 1FKF.pdb
Experimental binding affinity = -12.3 kcal/mol[197]
RMSD (Å)
Native
Complex

H
-80.749564

SE

-TS
0.11532

-24.94832
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SE
0.622585

G

SE

-55.801244

0.63317516

Native
Complex
(Seed 1)
Native
Complex
(Seed 2)
Native
Complex
(Seed 3)
Native
Complex
(Seed 4)
Native
Complex
(Seed 5)
Native
Complex
(Seed 6)
1.27036

-78.044307

0.106613

-24.4467

0.578165

-53.5976

0.5879125

-84.624617

0.126903

-26.0078

0.660703

-58.61683

0.6727799

-78.489595

0.120415

-25.2885

0.5781

-53.20114

0.5905077

-78.976578

0.127013

-22.5616

0.571974

-56.41497

0.5859066

-80.130134

0.118834

-26.0984

0.616361

-54.03169

0.627712

-80.615289

0.122224

-26.0296

0.647446

-54.58568

0.6588817

-81.861514

0.102454

-23.579446

0.554917

-58.282068

0.56429575

1.44909

-78.91196

0.103488

-25.718234

0.618171

-53.193726

0.6267736

1.46068

-81.633371

0.134721

-25.394066

0.584217

-56.239305

0.59954921

1.48019

-82.596128

0.129781

-25.497832

0.61714

-57.098296

0.63063848

1.49149

-80.597293

0.100088

-25.327878

0.598393

-55.269415

0.60670569

1.49149

-80.165938

0.101389

-25.070764

0.603344

-55.095174

0.61180365

1.52494

-78.886774

0.114555

-24.423028

0.621912

-54.463746

0.6323744

1.55528

-78.025116

0.117429

-25.293182

0.601295

-52.731934

0.61265426

1.60316

-77.379329

0.119061

-25.112074

0.651744

-52.267255

0.66252982

1.6833

-71.25694

0.134968

-24.735518

0.638892

-46.521422

0.65299261

1.73739

-79.888923

0.1107

-25.799912

0.627612

-54.089011

0.63730002

1.75264

-77.991309

0.107648

-25.756112

0.592129

-52.235197

0.60183457

1.75589

-95.696365

0.167537

-24.224884

0.666951

-71.471481

0.68767164

1.76704

-74.759709

0.105003

-23.044406

0.595143

-51.715303

0.60433502

1.78088

-85.307949

0.124506

-24.881022

0.631261

-60.426927

0.64342225

1.79503

-66.501126

0.114736

-24.251572

0.548968

-42.249554

0.56082993

1.80701

-82.517665

0.21449

-24.364348

0.604879

-58.153317

0.64178233

1.81334

-83.72354

0.110804

-26.370124

0.61316

-57.353416

0.62309125

1.85701

-65.881828

0.09949

-23.374782

0.521838

-42.507046

0.53123738

1.87989

-57.03092

0.123168

-22.569508

0.565494

-34.461412

0.57875195

1.88541

-72.722242

0.141328

-24.272778

0.593105

-48.449464

0.60971071

1.89224

-74.240793

0.126636

-27.7375

0.675852

-46.503293

0.6876137

1.89458

-53.985551

0.092278

-20.067932

0.463233

-33.917619

0.47233467

1.89578

-90.686041

0.137527

-27.433006

0.693599

-63.253035

0.70710201

1.93298

-77.24912

0.115568

-25.971982

0.633303

-51.277138

0.64376133
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1.93887

-81.493451

0.109929

-23.218954

0.617758

-58.274497

0.62746261

1.96531

-86.354952

0.121288

-25.895418

0.650466

-60.459534

0.66167726

1.96876

-80.39885

0.114027

-25.3684

0.605344

-55.03045

0.61598987

2.00267

-57.364231

0.116159

-17.573766

0.543955

-39.790465

0.55621934

2.00629

-70.693377

0.167243

-23.96641

0.581723

-46.726967

0.6052866

2.04332

-54.769576

0.087087

-20.296586

0.486694

-34.47299

0.4944241

2.04332

-54.769576

0.087087

-20.296586

0.486694

-34.47299

0.4944241

2.10115

-65.297386

0.100136

-22.588142

0.574894

-42.709244

0.58354977

2.11561

-78.407442

0.117777

-24.933494

0.602724

-53.473948

0.61412347

2.21592

-73.704709

0.108319

-23.80473

0.575253

-49.899979

0.5853623

2.27754

-65.14944

0.126586

-24.946286

0.60457

-40.203154

0.61768026

2.41055

-59.151986

0.084341

-22.394864

0.509047

-36.757122

0.51598668

2.46638

-69.321604

0.099528

-23.109054

0.604994

-46.21255

0.61312606

2.49382

-73.418612

0.108266

-23.375706

0.590613

-50.042906

0.6004542

2.56296

-67.177434

0.104443

-23.802268

0.656956

-43.375166

0.66520638

2.62764

435.728063

0.406923

-32.23058

0.751181

467.958643

0.85431799

2.63338

-92.216578

0.13104

-25.40859

0.650292

-66.807988

0.66336353

2.63448

-75.297402

0.147854

-23.616038

0.64098

-51.681364

0.65781165

2.67578

-82.153985

0.107841

-24.14492

0.615941

-58.009065

0.62531032

2.75532

434.041458

0.419681

-30.861666

0.778313

464.903124

0.88425294

2.86214

-59.797513

0.110001

-20.842808

0.515015

-38.954705

0.52663144

2.99392

-59.129056

0.083655

-24.267662

0.576713

-34.861394

0.5827487

3.14454

426.583489

0.453695

-28.384916

0.730227

454.968405

0.85969217

3.39517

383.135297

0.406718

-33.931028

0.832852

417.066325

0.92685597

3.51823

-74.882738

0.144277

-22.21655

0.627252

-52.666188

0.64363105

3.57472

395.047766

0.395676

-32.65872

0.723874

427.706486

0.8249564

3.587

-79.937802

0.123294

-26.191564

0.66064

-53.746238

0.67204659

3.62175

-89.027667

0.108159

-24.84515

0.713023

-64.182517

0.72117971

3.85991

370.040064

0.422476

-29.869258

0.727936

399.909322

0.84165123

4.0147

-70.932334

0.13602

-24.392372

0.60178

-46.539962

0.61696078

4.1087

-82.386442

0.173786

-25.90425

0.655313

-56.482192

0.67796512

4.1087

-82.386442

0.173786

-25.90425

0.655313

-56.482192

0.67796512

4.15034

629.63333

0.524061

-31.319138

0.746604

660.952468

0.91217184

4.25168

-63.716139

0.116735

-23.770586

0.539756

-39.945553

0.55223509

4.3843

-78.209085

0.096006

-23.241962

0.649495

-54.967123

0.65655229

4.39121

468.043829

0.453879

-29.644598

0.791807

497.688427

0.91266887

4.41258

-97.255179

0.103283

-22.967212

0.672684

-74.287967

0.68056678

4.61119

-63.798162

0.107218

-23.902466

0.590527

-39.895696

0.6001815

4.62147

-68.397403

0.189806

-24.13882

0.699383

-44.258583

0.72468124
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4.62147

-68.397403

0.189806

-24.13882

0.699383

-44.258583

0.72468124

4.62817

-69.029882

0.125454

-23.006796

0.588071

-46.023086

0.60130376

4.70342

-64.310173

0.14207

-22.670128

0.59182

-41.640045

0.60863355

4.80914

-77.195855

0.132886

-22.162246

0.596642

-55.033609

0.61126129

4.99681

368.809352

0.412561

-31.353824

0.760482

400.163176

0.86518174

5.00252

1089.811159

0.760568

-49.712238

1.155736

1139.5234

1.38354233

5.02869

-62.114134

0.119157

-21.63399

0.495629

-40.480144

0.50975141

5.04295

-73.408575

0.111447

-23.418662

0.547985

-49.989913

0.559203

5.17912

-55.57466

0.104344

-20.872376

0.598304

-34.702284

0.60733463

5.2297

-91.663816

0.167282

-26.935794

0.76482

-64.728022

0.78290031

5.2473

368.153332

0.402923

-31.433196

0.79083

399.586528

0.8875579

5.2626

-79.432059

0.191165

-23.564556

0.629757

-55.867503

0.65813216

5.39045

-71.399275

0.125067

-21.13133

0.564297

-50.267945

0.57799036

6.76027

-66.521227

0.206533

-22.259888

0.633382

-44.261339

0.66620465

Calculated percent change in binding affinities:

The following table contains the percent change in binding affinity for each proteinligand complexes and averaged over all complexes, within the respective RMSD blocks.
The standard deviation is given in following column.
Table 6. Percent change in binding affinity within respective RMSD block.
1D7J
RMSD (Å)

%|G|

SD

<2

27.9944399

22.1806389

>2 & <3

29.1573733

19.7072639

>3 & <4

39.3971762

37.0560615

>4

43.7803131

45.4465559

Native

0

0

2IFB
RMSD (Å)

%|G|

SD

<2

11.2745095

7.23872832

>2 & <3

19.9711787

13.8033657

>3 & <4

20.0172674

12.1059581
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>4

33.4168703

31.826922

Native

0

0

5CYH
RMSD (Å)

%|G|

SD

<2

14.0266604

7.66733623

>2 & <3

20.7291937

13.2280315

>3 & <4

20.871563

9.22298102

>4

18.5894724

12.2604389

Native

0

0

1LKK
RMSD (Å)

%|G|

SD

<2

10.0211086

9.4687308

>2 & <3

12.3483163

9.23509458

>3 & <4

25.546895

12.5156185

>4

34.579635

15.7516471

Native

0

0

1FKF
RMSD (Å)

%|G|

SD

<2

10.5888365

10.8771551

>2 & <3

21.7787977

11.8545577

>3 & <4

8.10694889

6.06447885

>4

16.7695947

11.8734506

Native

0

0

14.78111

SD
7.54470507

>2 & <3

20.79697

5.97759576

>3 & <4

22.78797

11.2955653

>4

29.42718

11.4689605

Native

0

0

Averaged Over
all
RMSD (Å)
<2

%|G|
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APPENDIX B

SUPPLEMENTARY INFORMATION FOR CHAPTER TWO

Table AB.1: The binding affinities of all the mutants and wild type structures towards
the MC/CA substrate. The mean energies are reported in kcal/mole with standard error in
the following column.

Mutants

H

SE

-TS

SE

SE

i13a

-61.4247

0.084285

-33.8248

1.159287

-27.5999

1.162347

i13l

-64.9968

0.092243

-34.2049

1.044125

-30.792

1.048192

g17e

-62.5295

0.08218

-32.2729

0.986579

-30.2567

0.989996

v32i

-65.3338

0.098566

-32.0303

0.937378

-33.3036

0.942546

m36v

-61.6208

0.093028

-33.9474

0.89588

-27.6735

0.900697

m36i

-63.5214

0.090369

-37.9317

1.111437

-25.5897

1.115105

m36a

-61.7167

0.090469

-34.4921

0.98662

-27.2246

0.990759

n37s

-61.8055

0.083012

-32.3233

1.045469

-29.4822

1.048759

n37d

-65.9411

0.092432

-38.4088

1.102619

-27.5323

1.106486

n37q

-61.3851

0.091404

-33.0841

1.087259

-28.3011

1.091094

g40e

-61.5837

0.094547

-33.0955

1.088237

-28.4882

1.092336

k43r

-64.6444

0.090866

-34.8902

1.098932

-29.7542

1.102682

m46v

-62.0327

0.090468

-35.6025

1.017937

-26.4302

1.021949

m46t

-64.4673

0.099904

-34.1156

1.018683

-30.3517

1.02357

g48e

-66.629

0.123129

-39.9954

1.142817

-26.6336

1.149431

g48v

-69.6779

0.102921

-35.6938

1.032483

-33.9841

1.0376

l63p

-63.163

0.094604

-34.6731

0.906709

-28.49

0.911631
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GS

l63v

-61.7616

0.103422

-35.9113

1.02891

-25.8503

1.034095

l63k

-68.1291

0.087068

-40.4848

1.037233

-27.6443

1.040881

l63g

-66.429

0.084319

-35.3906

1.009001

-31.0384

1.012518

l63a

-66.4265

0.095532

-37.5901

1.199584

-28.8365

1.203382

g68e

-65.3205

0.093386

-38.8766

1.156544

-26.444

1.160308

h69q

-62.5469

0.108003

-34.1858

1.015799

-28.3611

1.021524

h69y

-71.7393

0.095738

-36.6708

1.139597

-35.0685

1.143611

h69a

-65.6638

0.097901

-31.3036

1.241289

-34.3601

1.245144

a71l

-64.8642

0.089519

-35.7442

0.990664

-29.12

0.9947

a71t

-71.439

0.099204

-37.5238

1.023101

-33.9153

1.027899

a71g

-65.7517

0.096475

-36.0125

0.985569

-29.7393

0.99028

v77k

-62.7329

0.105156

-35.6966

1.182801

-27.0363

1.187466

v77l

-62.94

0.111071

-33.5639

0.995191

-29.3761

1.00137

v77i

-63.7596

0.094357

-34.4918

1.069006

-29.2678

1.073162

v77a

-57.5645

0.105802

-34.6001

1.052605

-22.9644

1.057909

v82i

-66.47

0.099632

-34.4111

1.146153

-32.059

1.150475

v82a

-63.2452

0.094301

-33.806

0.987082

-29.4392

0.991576

v82l

-61.7741

0.090315

-34.1393

1.01639

-27.6348

1.020395

v82g

-62.2093

0.087901

-36.6276

1.204683

-25.5818

1.207886

n88d

-66.4672

0.087265

-37.3541

1.039966

-29.1132

1.043621

i93l

-61.948

0.089661

-35.7891

1.063574

-26.1589

1.067347

i93a

-65.9971

0.089704

-35.7541

1.042918

-30.2431

1.046769

g94e

-57.2807

0.091632

-32.0617

0.987694

-25.2191

0.991935

wt

-61.4235

0.088198

-39.2854

1.032284

-22.1381

1.036045
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Table AB.2: The binding affinities of all the mutants and wild type structures towards
the transition state analogue corresponding to the MC/CA substrate. The mean energies
are reported in kcal/mole with the standard error in following column.

SE

-TS

SE

i13a

-87.1343

0.110586

-36.8217

1.211302

-50.3126

1.21634

i13l

-87.8429

0.10825

-39.3112

1.132012

-48.5317

1.137176

g17e

-84.7531

0.099002

-37.9752

1.180029

-46.7778

1.184175

v32i

-88.5417

0.101283

-38.1173

1.145245

-50.4245

1.149715

m36v

-90.0149

0.107252

-41.1197

1.147773

-48.8953

1.152773

m36i

-85.7079

0.100256

-38.4605

1.143583

-47.2475

1.147969

m36a

-83.9506

0.098677

-38.078

1.049357

-45.8725

1.053986

n37s

-88.6927

0.118596

-36.4497

1.126932

-52.2431

1.133155

n37d

-79.1307

0.10182

-39.1252

1.156057

-40.0054

1.160532

n37q

-82.2196

0.116751

-39.2061

1.110314

-43.0135

1.116435

g40e

-75.9423

0.112809

-38.25

1.12774

-37.6923

1.133368

k43r

-88.0244

0.105611

-37.162

1.062024

-50.8624

1.067262

m46v

-97.6834

0.105921

-43.2685

1.1631

-54.4149

1.167913

m46t

-84.2464

0.11061

-38.0921

1.094846

-46.1542

1.100419

g48e

-73.5539

0.102521

-35.8008

1.071379

-37.7531

1.076273

g48v

-91.4041

0.10213

-38.5531

1.155831

-52.8511

1.160334

l63p

-85.9812

0.100585

-37.6951

1.082316

-48.286

1.08698

l63v

-86.4485

0.104139

-40.9508

1.081792

-45.4977

1.086793

l63k

-93.6486

0.10483

-37.5526

1.11499

-56.096

1.119907

l63g

-87.9916

0.104273

-37.4295

1.140728

-50.5621

1.145484

l63a

-87.7329

0.096801

-40.5782

1.15096

-47.1547

1.155024
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GT

H

Mutants

SE

g68e

-77.8527

0.103745

-38.949

1.112852

-38.9037

1.117677

h69q

-86.2313

0.097717

-37.4404

1.032956

-48.7909

1.037568

h69y

-93.1042

0.108702

-39.3333

1.223202

-53.7709

1.228022

h69a

-83.1344

0.101177

-35.0961

1.059667

-48.0383

1.064486

a71l

-82.3045

0.108139

-37.4812

1.140884

-44.8233

1.145998

a71t

-94.6324

0.102572

-38.1378

1.035745

-56.4946

1.040812

a71g

-89.4727

0.100441

-38.0418

1.244777

-51.4309

1.248823

v77k

-98.6776

0.098711

-40.2531

1.147883

-58.4246

1.152119

v77l

-82.0941

0.093702

-37.5572

1.049512

-44.537

1.053687

v77i

-90.1835

0.0947

-37.968

1.014577

-52.2155

1.018987

v77a

-86.278

0.102356

-39.8335

1.100628

-46.4444

1.105377

v82i

-91.7837

0.103785

-43.9451

1.202279

-47.8385

1.20675

v82a

-82.1556

0.102785

-40.9517

1.158702

-41.2039

1.163252

v82l

-85.6853

0.106311

-37.4827

1.182387

-48.2026

1.187157

v82g

-84.9443

0.118185

-36.966

1.179196

-47.9783

1.185104

n88d

-78.8088

0.106642

-35.7657

1.148305

-43.0431

1.153246

i93l

-88.5851

0.099062

-40.0603

1.109916

-48.5248

1.114328

i93a

-87.534

0.107019

-39.8231

1.218833

-47.7109

1.223522

g94e

-77.0317

0.105226

-40.5565

1.072927

-36.4752

1.078075

wt

-88.9466

0.102189

-36.9362

1.263277

-52.0104

1.267403
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Table AB.3: The experimental and calculated ranks of activities.

Mutants

g17e

Experimental
% Activity

Experimental
Rank

35

5

Gactive=
GT-GS
(kcal/mol)

-16.5212

Gactive=GT
(kcal/mol)

5

-46.7778

Calculated
Rank of
Activities
based on
Equation
3.8
6

m36v

30

4

-21.2218

8

-48.8953

8

n37s

55

8

-22.7608

10

-52.2431

11

g40e

0

1

-9.2041

1

-37.6923

1

k43r

50

7

-21.1083

8

-50.8624

9

m46v

100

11

-27.9847

11

-54.4149

12

m46t

40

6

-15.8026

4

-46.1542

5

g48e

3

3

-11.1195

2

-37.7531

1

l63p

98

10

-19.796

6

-48.286

7

l63v

62

9

-19.6474

6

-45.4977

4

n88d

0

1

-13.93

3

-43.0431

3

100

12

-29.8723

12

-52.0104

10

wt
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Calculated
Rank of
Activities based
on Equation 3.7
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